University of Nebraska Medical Center

DigitalCommons@UNMC
Theses & Dissertations

Graduate Studies

Fall 12-14-2018

Development of Macromolecular Prodrugs for the Treatment of
Chronic Inflammatory Pain
Laura Weber
University of Nebraska Medical Center

Follow this and additional works at: https://digitalcommons.unmc.edu/etd
Part of the Pharmacy and Pharmaceutical Sciences Commons

Recommended Citation
Weber, Laura, "Development of Macromolecular Prodrugs for the Treatment of Chronic Inflammatory Pain"
(2018). Theses & Dissertations. 323.
https://digitalcommons.unmc.edu/etd/323

This Dissertation is brought to you for free and open access by the Graduate Studies at DigitalCommons@UNMC. It
has been accepted for inclusion in Theses & Dissertations by an authorized administrator of
DigitalCommons@UNMC. For more information, please contact digitalcommons@unmc.edu.

DEVELOPMENT OF MACROMOLECULAR PRODRUGS FOR
THE TREATMENT OF CHRONIC INFLAMMATORY PAIN

By
Laura Weber

A DISSERTATION

Presented to the Faculty of
The Graduate College of the University of Nebraska
In Partial Fulfillment of the Requirements
For the Degree of Doctor of Philosophy

Department of Pharmaceutical Sciences

Under the Supervision of Professor Dong Wang

University of Nebraska Medical Center
Omaha, Nebraska

December 2018

TABLE OF CONTENTS

ACKNOWLEDGEMENTS .............................................................................................. I
ABSTRACT ................................................................................................................. IV
LIST OF FIGURES ...................................................................................................... VI
LIST OF TABLES ...................................................................................................... VIII
LIST OF SCHEMES .................................................................................................... IX
LIST OF ABBREVIATIONS.......................................................................................... X
LIST OF CONTRIBUTORS ....................................................................................... XIV

CHAPTER 1. INTRODUCTION
1.1

1.2

Rheumatoid arthritis ............................................................................................. 2
1.1.1

The risk factors of RA ................................................................................ 3

1.1.2

Pathogenesis and progression of pain in RA ............................................. 4

Current treatment strategies for pain in RA .......................................................... 5
1.2.1

NSAIDs ...................................................................................................... 5

1.2.2

Glucocorticoids .......................................................................................... 7

1.2.3

Synthetic DMARDS .................................................................................. 10

1.2.4

Biologic DMARDs .................................................................................... 13

1.2.4.1

TNF-α Inhibitors ............................................................................. 13

1.2.4.2

IL Inhibitors .................................................................................... 13

1.2.4.3

1.3

T-cell activation and CD20 activity inhibitors .................................. 15

1.2.5

Opioids..................................................................................................... 16

1.2.6

Antidepressants ....................................................................................... 19

Strategies to improve PK/BD of pharmacological entities for RA pain ............... 22
1.3.1

Macromolecular arthrotropism and synovial retention in inflammatory

joints .................................................................................................................... 22
1.3.2

1.3.2.1

Liposomes ...................................................................................... 24

1.3.2.2

Polymeric nanoparticles ................................................................. 26

1.3.2.3

HPMA copolymers ......................................................................... 28

1.3.3
1.4

Drug carriers to target inflamed synovium ................................................ 24

Acid-labile linker between drug and macromolecule backbone ................ 29

Summary ........................................................................................................... 31

CHAPTER 2. HPMA COPOLYMER-BASED DEXAMETHASONE
TREATMENT OF ARTHRITIC PAIN AND INFLAMMATION

FOR

THE

2.1 Introduction ........................................................................................................... 34
2.2 Materials and methods.......................................................................................... 35
2.3 Results .................................................................................................................. 47
2.4 Discussion ............................................................................................................ 63
2.5 Conclusion ............................................................................................................ 66

CHAPTER 3. HPMA COPOLYMER-BASED
TREATMENT OF ARTHRITIC PAIN

HYDROMORPHONE

FOR

THE

3.1 Introduction ........................................................................................................... 67
3.2 Materials and methods.......................................................................................... 68
3.3 Results .................................................................................................................. 79
3.4 Discussion ............................................................................................................ 91
3.5 Conclusion ............................................................................................................ 95

CHAPTER 4. SUMMARY ........................................................................................... 96

I

ACKNOWLEDGEMENTS

It goes without saying that without the guidance of my mentor Dr. Dong Wang, I
would not be in the position that I am today, primed for a rewarding career as a
pharmaceutical scientist. Through his encouragement and support from my beginnings
in his laboratory as a technician, I have been successful in the role of a graduate student,
despite the times when I harbored overwhelming self-doubt in my own capabilities. His
meticulous standards of research and the presentation thereof have been firmly
established into my own approach to the scientific method.

The efficiency,

independence of thinking, analytical mindset, as well as the boldness to go above and
beyond have become my modus operandi as part of the example he has set. I would
like to thank him for seeing me through to the end, and for always having my future
career in perspective.

The members of my supervisory committee have consistently served as excellent
mentors during their time as my academic council. Dr. Geoffrey Thiele has always been
a delight to talk to, whether it be about research matters or otherwise, and his support
and sincerity have helped motivate me through the final push towards graduation. Dr.
Hanjun Wang has graciously given me insight and advice relating to his expertise, and
I am grateful for his assistance and his words of encouragement. Dr. Joseph Vetro has
always been willing to discuss scientific issues and offer advice pertaining to my
research, or even involving my career path and which road I may like to take.

The people with whom I have worked each day throughout my graduate studies
have no doubt had a positive impact on my graduate career as well as my everyday life.

II

Dr. Zhenshan Jia has been there since day one, always making me feel welcomed and
at ease within the lab. He has tirelessly shared his chemistry knowledge and skill
throughout the years, with my best interest in mind. Dr. Xiaobei Wang has been my rock
within the lab for the duration of my studies. Her patience and friendship have often
been the catalysts to motivate me and keep me enduring. During the time he has been
here, Dr. Rungguo Ren has always been a pleasant colleague and has worked
extremely diligently to produce and characterize the necessary chemical components of
my research. Dr. Xin Wei has constantly supported me and graced me with incredibly
useful knowledge from her experience as a graduate student. Her husband Gang Zhao
always offered his technically-savvy hands when instrumental issues arose. Xiaoyan
Wang, the past lab manager, was always very organized and efficient, and often lent a
sympathetic ear to my struggles. Ningrong Chen has always been willing to assist me
with the last few experiments for my dissertation.

I want to extend special thanks to all the others affiliated with UNMC who have
been an integral part of my success. Dr. Subodh Lele has helped the lab for several
years with pathological feature identification and grading of histology samples, and he
has generously provided me with his expertise for my own project. I spent a good
amount of time at the confocal core facility, and always felt like a priority when I needed
assistance at the microscope. The tissue facility efficiently produced quality histology
slides for my research. All PSGP courses instructors devoted their time and energy into
ensuring students’ success.

I am especially grateful for the Department of

Pharmaceutical Sciences staff, including Jamie Cook, Elaine Payne, Renee Kaszynski,
Tami Houdesheldt, and Katina Winters, who, although she has long since moved on to
another position elsewhere, has remained a shoulder of support and a great friend with
concern for my welfare.

III

In addition to all the individuals within the academic setting who have seen me
progress along the way, it bears mentioning the sources of funding for my project. Along
with the two National Institute of Health R01 grants that have assisted me, I also want to
acknowledge the graduate student fellowship provided by UNMC that funded me for two
years. These have allowed me to continue my research without the added stress of
worrying whether I could secure my position as a graduate research assistant, and make
enough money to live while inching further and further towards my goal of obtaining my
advanced degree.

I have never been more grateful for the support of my close friends and family
than during my time in graduate school. They know more than anyone else the struggles
that I have come across these past few years especially, both academically and
personally. Many times I have felt like throwing in the towel, and each of those times
they have shone like a beacon of hope guiding me towards the end. To me, the ultimate
triumph here is never having given up.

I hope they know how valuable their

encouragement has been, and I shall never forget their unwavering belief in me.

IV

DEVELOPMENT OF MACROMOLECULAR PRODRUGS FOR
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Chronic pain afflicts millions of people worldwide. Particularly, the inflammatory
conditions in the incurable disease rheumatoid arthritis (RA) generate persistent pain
in its sufferers, for which a number of different analgesics have been prescribed, such
as glucocorticoids (GCs) and opioids.

However, administration of these pain-

mitigating pharmaceutics is implicated in the development of adverse systemic effects
due to their non-specific tissue distribution and quick excretion, eliciting the need for
high dosing frequencies.

To address this issue, this thesis is focused on the

development of prodrugs based on a macromolecular design approach to instill
preferential inflammation-targeting and retentive properties to common analgesics.
Previously within our lab, an HPMA copolymer prodrug of the common GC
dexamethasone (P-Dex) was tested for its antirheumatic properties in a rodent model
of adjuvant-induced arthritis (AIA). The first part of this project, therefore, involved
further evaluation of the pain-alleviating properties of P-Dex. We demonstrated that a
single systemically-administered dose of the prodrug significantly reduced the pain
response for a duration of twenty-one days, versus equivalent doses of free Dex given
daily. It was confirmed that both the sustained analgesia and anti-inflammatory effects
conferred by P-Dex is due to its enhanced uptake within inflamed tissue and

V

subsequent retention by phagocytosing immune cells within the arthritic synovium and
synovial cavity. Moreover, the macromolecular P-Dex copolymer greatly tempered the
co-morbidity of enhanced bone turnover, as is often observed in RA. To expand the
clinical repertoire of improved analgesic therapies for RA, we then synthesized and
tested the pain-alleviating properties of an HPMA copolymer of the opioid
hydromorphone (HMP), a very potent drug that has been implicated in deleterious
effects on the central nervous system (CNS) by crossing the blood-brain barrier (BBB).
Though the analgesic effects lasted only throughout the dosing day, there was
sustained presence of this prodrug (P-HMP) for up to seven days within the AIA knee
joint, confirmed to be mediated by the resident inflammatory cells. In contrast to the
free drug, the spinal cord analgesic effects of P-HMP were greatly attenuated.
Therefore, it can be reasoned that opioid-induced CNS depressive effects could be
mitigated by way of the polymeric scaffold’s inability to cross the BBB.

Though there remain optimization strategies to be implemented in the design of
these macromolecular analgesics, we have successfully demonstrated their improved
therapeutic efficacies in the treatment of pain related to RA. Through instilling arthrotropic
and retentive properties to small molecule drugs, the prodrug approach can not only more
effectively relieve pain versus free drugs alone, but may also curtail harmful systemic side
effects associated with off-target biodistribution. In conclusion, macromolecular prodrugs
demonstrate great potential as a clinically-relevant approach to mitigate the pain
accompanying such chronic inflammatory conditions as those present in the pathology of
RA.
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CHAPTER 1
INTRODUCTION

Pain is arguably one of the most fundamental attributes of sentient organisms.
A direct consequence of being alive and responsive to stimuli, it has been generally
defined as "an unpleasant sensory and emotional experience associated with actual or
potential tissue damage, or described in terms of such damage," according to the
International Association for the Study of Pain. Its triggers are numerous, and the
experience subjective from person to person. Furthermore, although initially short-lived,
acute pain arising as a normal stimulus to alert the person to possible injury can cause
further complications such as immobility, rendering the suffering persistent and thus
causing long-term disability and overall decline in everyday quality of life.

In

inflammatory conditions like rheumatoid arthritis (RA), pain is a primary manifestation
throughout the various stages of the disease development. This persistent, unyielding
type of pain is broadly classified as chronic, and exists for the duration of the disease,
ergo for the lifetime of the patient.

A number of therapeutic strategies are often

employed to attenuate and attempt to alleviate the chronic pain associated with RA,
among which include analgesics such as nonsteroidal anti-inflammatory drugs
(NSAIDs), glucocorticoids (GCs), disease-modifying antirheumatic drugs (DMARDs),
and opioids, and even antidepressant medications have been explored as therapeutic
agents. However, effective doses are usually transient and require repeated intake to
achieve sustained therapeutic effect.

In the following chapters, I will discuss the approaches that we have taken to
address the issue of chronic pain in RA. Existing therapies all have their downfalls and
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may prove to be either subpar in their ability to reduce the pain itself, or in their biological
safety with continued use. By understanding the physiological manifestations of chronic
pain, we can tailor currently-used analgesics to more efficiently and more effectively
deliver pain relief in inflammatory ailments like RA. We have sought to prove the
superior effects of our synthetically-modified analgesics.

1.1

Rheumatoid arthritis
Rheumatoid arthritis is a chronic, progressive, and incurable autoimmune

disease characterized by joint synovial inflammation in a symmetric pattern, which leads
to painful deformity and immobility, primarily affecting the fingers, wrists, feet, and
ankles.1 It is present in approximately 0.5-1% of the worldwide population,2 in nearly
three times as many women as in men, and approximately 1.5 million people suffer from
the disorder in the U.S. alone.3 Hallmarks of the disease include production of the
autoantibodies rheumatoid factor (RF) and anti–citrullinated protein antibody (ACPA),
synovial hyperplasia (swelling resulting from cell proliferation), hypervascularization,
and infiltration of inflammatory immune cells. Through cellular pathways and activation
of a series of cytokines, these cells can activate monocytes/macrophages and fibroblastlike synoviocytes (FLS) to overstimulate production of proinflammatory cytokines such
as interleukin (IL)-1 and tumor necrosis factor alpha (TNF-α), and to locally secrete
tissue-degrading enzymes.4 Systemic inflammation can occur as well, such as in the
organs and tissues of the cardiovascular and pulmonary systems.5 If left untreated,
joints can become completely destroyed by the infiltrating antibodies, and comorbidities
such as cardiovascular disease and infection can result in mortality. Its catalyst remains
unknown, but there are postulated to exist several risk factors that play a role in the
development of RA.

These include various genetic and environmental factors,
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combinations of which can greatly increase an individual’s susceptibility to RA. Once
activated, adaptive and innate immune responses play roles in the progression of RA,
invariably contributing to the debilitating pain that its patients suffer.

1.1.1

The risk factors of RA
Genetic predisposition to RA has been discovered in particular class II major

histocompatibility complex (MHC) haplotypes in patients with RF or ACPA, which reacts
to the citrulline residues enzymatically converted from arginine residues in the presence
of inflammation.6 One of the most well-established contributing factors is certain alleles
of the human leukocyte antigen (HLA)-DRB1 locus containing a shared epitope, or a
common amino acid motif, which has been discovered in patients with RA and may
influence T-cell repertoire selection, antigen presentation, or may alter peptide affinity.7
Several other genes have been implicated even in ACPA-negative RA. Altogether, over
100 chromosomal loci are associated with disease risk and progression,5 most of which
involve immune effector or regulatory gene products.

The initiation of RA in those who are genetically susceptible can be caused by a
myriad of factors. Infectious agents such as bacteria or viruses can induce the formation
of immune complexes that in turn can prompt the production of RF. Smoking8 and other
forms of bronchial stress, such as exposure to silica, increase the risk of the disease
among persons with susceptibility isotype HLA–DR4, and promote post-translational
modifications that result in quantitative or qualitative alteration in citrullination of mucosal
proteins.7
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1.1.2

Pathogenesis and progression of pain in RA
Arthritic pain can plague a person for a lifetime, once the disease has progressed

and become a chronic issue. Despite the prevalence of joint pain worldwide, there is
limited knowledge on the precise mechanisms and mediators of this pain. The knee
joints harbor a variety of nerve endings responsible for both sensory and sympathetic
functions; i.e. both afferent nerves that carry sensory information to the central nervous
system (CNS), and nerves responsible for autonomic responses such as vasoconstrictor
tone to regulate blood flow through the joint.9 Nociceptors, the pain-sensing nerves,
undergo sensitization through the mechanical forces applied by plasma fluid exuding
into the joint to form edema, and by the effects of the inflammatory soup of such
mediators as peptides, eicosanoids, and ion channel ligands. Afferent neurons such as
low threshold nociceptive mechanoreceptors with thick and thin myelinated axons (Aβ and
Aδ fibers) display increased activity upon mechanical stimulation of the joint and joint
movement. Moreover, high mechanical threshold nociceptors begin to respond to light
pressure applied onto the joint.
unmyelinated (C) fibers.
stimulation.10

Most of these units are thin myelinated (Aδ) or

Even silent nociceptors show activity upon mechanical

Together, these phenomena are indicative of sensitization due to a

reduction in the tolerance threshold and an increase in the magnitude of the pain
response to noxious stimulation, denoted as hyperalgesia. Moreover, allodynia can
develop, meaning that previously benign stimuli can be rendered effective, and even
spontaneous pain with no apparent effector can ensue.11 These types of pain caused
by damage to the somatosensory nervous system are together deemed neuropathic, an
unyielding sensation that is often carried with malignancies beyond that of a transient
injury or burn that may cause short-lived acute nociception.

Additionally, cerebral

immune activation manifests as microglia and astrocyte production of proinflammatory
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cytokines within the CNS, and these factors have a direct effect on neurotransmission and
pain.12,13 In particular, intrathecal IL-1β is notably increased in conditions of peripheral
inflammation such as RA, stimulating cyclooxygenase-2 (COX-2) activity and
prostaglandin (PG) production, such as prostaglandin E2 (PGE2),14 which act on sensory
neurons to produce pain. Thus, the pain associated with RA is a combination of both
peripheral and central sensitization mechanisms.

1.2

Current treatment strategies for pain in RA
Along with prevention of joint and organ damage, pain control is a crucial aspect

of the treatment of RA. Several pharmacologic options exist for the mitigation and/or
alleviation of pain symptoms, either as their most prevalent effect or as a combination
of anti-nociceptive and anti-inflammatory actions.

1.2.1

NSAIDs
Nonsteroidal anti-inflammatory drugs, commonly known as NSAIDs, are widely

used as analgesic agents for chronic pain conditions like RA. There exist over twenty
distinct drugs classified based on their chemical structures.15 This class of drugs inhibits
the synthesis of cyclooxygenase enzymes (COX-1 and/or COX-2), which are
responsible for the production of PGs through conversion of arachidonic acid present in
cell membrane phospholipids. Here, arachidonic acid, an omega-6 poly-unsaturated
fatty acid, is cleaved from cell membranes by one of several different phospholipase A2
(PLA2) enzymes,16 followed by a reaction mediated by the COX enzymes whereby the
free arachidonate is converted to the cyclic endoperoxide prostaglandin G2 (PGG2).
The next part of this biosynthesis involves a hydroperoxidase reaction in which PGG2 is
reduced to prostaglandin H2 (PGH2), an unstable intermediate that either spontaneously
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rearranges or is enzymatically converted to one of many isoforms of biologically active
PGs.17 The two COX isoforms are responsible for the formation of PGs with variable
biological capacities, COX-1 being expressed under basal conditions and rendering
biosynthesis of PGs that are involved in homeostatic functions, while COX-2 expression
is increased during inflammation.18

In this scenario, PGs mediate pathogenic

mechanisms such as the inflammatory response itself. Specifically, PGE2 is known to
regulate the function of many cell types including macrophages, dendritic cells, and T
and B lymphocytes to elicit both pro- and anti-inflammatory effects.19

As a pro-

inflammatory mediator, PGE2 simultaneously stimulates pain via sensitization of
peripheral nociceptors to the effects of mediators such as bradykinin or histamine,20 and
on central sites within the spinal cord and the brain through inducing prostanoid receptor
activation on neurons and microglia.21

Because they can effectively relieve both pain and stiffness associated with RA,
NSAIDs are typically prescribed as a first-line bridge therapy to minimize the initial
symptoms while waiting for more slowly-acting DMARDs to take effect. The prolonged
use of NSAIDs is concomitant with an array of systemic issues. For example, nonselective COX inhibitors cause lowering of stomach PG levels, which in turn causes loss
of gastric mucosal integrity via their interaction with COX-1, resulting in ulcers of the
stomach or duodenum internal bleeding. Other risks include kidney and liver failure,
heart attack, and stroke. NSAIDs differ in their relative affinities for inhibition of COX-1
versus COX-2.22 COX-2 selective inhibitors amend the issue of peptic ulceration, yet
they still cause cardiovascular problems. According to a systematic review of avoidable
drug-related hospital admissions, 11% of these visits are caused by NSAIDs alone.23
The risk of gastrointestinal, cardiovascular, and renal complications have been shown
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to increase within the first few weeks of NSAID treatment, and to persist for the duration
of the therapy.23–25

1.2.2

Glucocorticoids
Glucocorticoids (GCs) are a class of corticosteroid hormones endogenously

synthesized and regulated by the hypothalamic-pituitary-adrenal (HPA) axis. Some
naturally-occurring GCs include cortisone, cortisol (hydrocortisone), and aldosterone. In
particular, the neuroendocrine hormone cortisol is the most essential, being involved in
a myriad of cellular pathways relating to cardiovascular, immunologic, metabolic, and
homeostatic functions. It plays an immunosuppressant role in pain and inflammation by
preventing the release of inflammatory mediators such as IL-12, interferon gamma (INFγ), and TNF-α by antigen-presenting cells (APCs) and T helper (Th) 1 cells. In a
congruous fashion, cortisol simultaneously upregulates IL-4, IL-10, and IL-13, which
downregulate the expression of Th1 cytokines and stimulate the production of antiinflammatory Th2 cells. The induction of this Th2 shift is believed to be a protective
mechanism against overproduction of Th1 and proinflammatory cytokines with tissuedamaging potential.26

Cortisol’s exogenous counterpart, hydrocortisone, was

discovered in 1900. This drug’s first successful use was achieved in 1944 for the
treatment of pain and inflammation in RA patients, and shortly thereafter for medicating
the restrictive airways in asthmatics.27

However, this particular drug exhibited

mineralocorticoid side effects, such as hyponatremia and hypokalemia, spurring the
need to synthesize different GCs with more GC-specific, i.e. anti-inflammatory, activities.
Therefore, a multitude of new GCs were synthesized in the 1950s and 1960s, among
these being prednisone/prednisolone, methyl prednisolone, and fluorinated GCs such
as dexamethasone (Dex) and betamethasone.28 Along with inflammation, GCs reduce
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pain by inhibiting pro-inflammatory PG synthesis and by reducing vascular permeability
that results in tissue edema. GCs also have a direct effect within the CNS. Studies29
have shown that GC receptors are present within the central and peripheral nervous
systems, where their activation can modulate growth, differentiation, and development
of neurons. As lipophilic molecules, GCs can cross the blood-brain barrier (BBB) and
interact with their receptors present in the brain.30 These drugs have been shown to
mitigate neuropathic pain by reducing spontaneous discharge in an injured peripheral
nerve.31

Glucocorticoids prevail as the most effective anti-phlogistic and immune
suppressive substances known,32 and therefore remain in clinical practice for the
treatment of RA pain and inflammation. Usually, GCs are taken in conjunction with
DMARDs for fast, effective pain and inflammation relief before the disease-modifying
drugs are able to take effect. Temporary administration of GCs have been shown to
suppress RA progression and preserve joint function.33 In particular, Dex treatment is
still currently utilized as an effective agent in suppressing the symptoms of severe pain
and inflammation in RA.27

It exhibits six times the antirheumatic potency versus

prednisone, and about 25 to 30 times that of hydrocortisone.34 Nonetheless, even with
limited dose and duration, there can be marked deleterious systemic effects caused by
GC interaction with its pleiotropic targets.

The underlying issue with exogenous GCs is that of their transactivation of
certain genes. GCs bind to the glucocorticoid receptor (GR), which is present in the
cytosol of almost every cell within the body. Upon doing so, the resulting complex
promotes nuclear translocation and initiates a cascade of events which through DNA
binding directly upregulates the expression of certain proteins in the nucleus by inducing
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the transcription of genes such as those for gluconeogenesis.

Additional anti-

inflammatory outcomes result from transactivation by GCs, such as the upregulation of
lipocortin-1, which potentiates the anti-inflammatory effect through inhibition of PG
synthesis at the level of COX-2 and PLA2.35 Conversely, GC transrepression of key
inflammatory transcription factors inhibits the expression of pro-inflammatory proteins in
the cytosol by preventing the translocation of other transcription factors, namely, nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-κB) and activator protein 1
(AP-1), from the cytosol into the nucleus.36 There is such a complex interplay between
the two mechanisms, but the therapeutic benefit conferred by GCs is related primarily to
their transrepressive properties.

This promotes the downregulation of key pro-

inflammatory chemokines; epithelial adhesion molecules such as intercellular adhesion
molecule 1 (ICAM-1) and E-selectin, which together are implicated in the recruitment of
leukocytes to inflammatory sites; and cytokines such as TNF-α and IL-1, which are
released locally by macrophages and increase the expression of the aforementioned
adhesion molecules.37 More often than not, transactivation by GCs have detrimental
consequences, playing a role in the onset of many secondary disorders affecting multiple
systems, including the endocrine, cardiovascular, and musculoskeletal systems.
Perhaps the most severe and life-threatening complication from extended GC therapy
for RA is that of GC-induced osteoporosis.

Both increased bone resorption and

decreased bone formation occur through GC-induced osteoclastogenesis, and a
decrease in osteoblastic cell replication and differentiation is observed, along with
collateral apoptosis of mature osteoblasts.38 Even modest doses in even the first few
months of GC therapy have been known to greatly increase the risk of spinal and hip
fracture.39
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In an attempt to curtail the undesirable side effects of exogenous GCs, both
steroidal and steroid-based agonist compounds have been synthesized which can alter
GR-mediated gene expression profiles through selective activation of certain
mechanisms. These are referred to as dissociated compounds favoring GR monomer
formation, dubbed selective GC receptor agonists (SEGRAs) or modulators
(SEGRMs).40 However, since the therapeutic benefit of GCs has been discovered to be
a combination of both transrepression and transactivation, the positive effects of more
selective agonists may not be as robust as with conventional steroids. Much more
research is essential to determine the pharmacological profiles of these selective
entities. Moreover, as primarily is the case with SEGRMs, issues that may arise due to
systemic administration is not addressed as often as with topical skin and eye
preparations.41

1.2.3

Synthetic DMARDS
Disease-modifying antirheumatic drugs, or DMARDs, compensate for both

insufficiency of GCs to slow disease progression and lack of NSAID ability to address
the underlying causes of pain and inflammation in RA. These drugs are classified as
either synthetic (conventional or targeted) or biologic (original or biosimilar). Their
origins date back to the 1930s with the advent of using injectable gold to abate the
edema associated with RA, which in turn served as a pain-relief therapy. Biologic
DMARDs made their debut in 1998 with the approval of etanercept, a TNF inhibitor.
Both types of DMARDs have proven effective via either targeting the entire immune
system (synthetic) or via their actions on specific targets within the inflammatory process
(biologic or targeted synthetic). Typically, monotherapy is initially prescribed, with the
choice of DMARD depending on individualized patient characteristics and preferred
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biologic targets. If such an approach does not suffice, a conventional synthetic DMARD
can be prescribed in combination with others of its class, or it can be paired with one
biologic at a time, until disease remission is achieved.

Synthetic DMARDs work by targeting the destructive processes of RA through
mechanisms still not completely elucidated. Usually, the onset of therapeutic relief for
these drugs tends to be slow, with an average rate of three to six months before their
benefits can be observed. It is therefore recommended that DMARDs be prescribed
within three months after diagnosis of RA in order to significantly deter the radiographic
progression of the disease and to ease accompanying pain and inflammation. However,
methotrexate (MTX), the standard synthetic to which all other emerging DMARDs are
compared, can achieve remission within four to six weeks after initiation of therapy. It
has been the predominantly used DMARD for several decades. Originally used for
chemotherapy, its mechanisms of action on RA are thought to be through multiple
pathways different from its anti-cancer functions. In dosages used for RA, some of these
mechanisms include the inhibition of enzymes involved in purine metabolism, causing
inhibition of proliferation of inflammatory immune leukocytes;42 inhibition of T cell
activation and suppression of intercellular adhesion molecule expression by T cells;
selective down-regulation of B cells; and inhibition of methyltransferase activity,
suppressing aggressive FLS expression and therefore in turn decreasing their
production of proinflammatory cytokines and mediators.43 MTX is effective in controlling
the swelling, pain, and stiffness that result from inflammation in RA, yet there is
reportedly only a portion of patients with actual disease remission.44 Other synthetic
DMARDs on the market include sulfasalazine and leflunomide, which can both be used
together with MTX, and azathioprine, which is safe when combined with other classes
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of medications such as NSAIDs and corticosteroids. Drawbacks of these particular
drugs include heightened risk for infection and hepatotoxicity.45
Targeted synthetic DMARDs prevent induction of precise pathways within
immune cells. These include the drugs apremilast and tofacitinib (Tofa). Apremilast acts
as a selective inhibitor of the enzyme phosphodiesterase 4 (PDE4), which is most
prevalent in immune cells and degrades cyclic adenosine monophosphate (cAMP).
Increased cAMP levels appear to generally weaken monocyte inflammatory
functions.46,47

This medication is also responsible for inhibiting the spontaneous

production of TNF-α from human rheumatoid synovial cells, thereby contributing to pain
and inflammation resolution through the reduction of IL-1 oxidants and PGE2.

Its

therapeutic efficacy has been confirmed in a randomized, multicenter, double-blind,
placebo-controlled Phase III clinical trial in patients with psoriatic arthritis,48
distinguished from RA by painful, scabrous rashes on the skin and lack of circulating RF.
However, its Phase II trials in patients with active RA demonstrated no notable effect,
despite stable therapy. In contrast, Tofa, a potent, selective inhibitor of janus kinase
(JAK) 1 and 3, is specifically marketed for use in RA patients who have not responded
well to MTX. It acts through interference in the JAK-STAT (Signal Transducer and
Activator of Transcription) signalling pathway, an important part of cytokine
communication. Specifically, Tofa has been shown in a murine model of arthritis49 to
inhibit the production of inflammatory mediators and to suppress STAT1-dependent
gene expression in synovial cells, in turn affecting interferon influence on the overall
inflammatory response. Concern over its safety and efficacy, however, had prevented
its approval by European regulatory agencies until 2017;50 the USFDA is still required to
provide written warnings with the use of this drug, such as the possibility of malignancies
like infection and lymphoma.51 Its immunosuppressive effects can drive the immune
system to succumb to opportunistic pathogens.

13

1.2.4

Biologic DMARDs
A more thorough understanding of the immunopathogenic pathways in the

genesis of RA has led to the advent of newer, biologic DMARDs. These are fortified by
their unique specificities to molecular targets on cells involved in the progression of RA.
There are four types of biologic DMARDs, classified according to which molecular aspect
of the immune system they target. There are five TNF-α inhibitors, i.e. infliximab,
etanercept, adalimumab, certolizumab, and golimumab; two interleukin inhibitors,
tocilizumab and anakinra; one T-cell activation inhibitor, abatacept; and one CD20
activity blocker, rituximab.52

1.2.4.1

TNF-α Inhibitors
As a component in the acute phase reaction of RA, TNF-α is responsible for the

regulation of immune cells that are involved in the inflammatory response. Moreover,
for the purpose at hand, data has shown that it leads to more intensive, widespread and
prolonged activity within the CNS upon nociceptive stimulation. There seems to be a
direct correlation between TNF-α and the brain’s limbic regions associated with the
emotional and physical perception of pain. In mouse models of RA as well as in patients
with the disease, blockage of this cytokine’s activity by either infliximab or etanercept
rapidly abrogates CNS pain responses, at a rate much faster than that commonly
observed with the anti-inflammatory effects generated by such inhibitors.53,54

1.2.4.2

IL Inhibitors
Both IL-1 receptor antagonist anakinra and IL-6 transmembrane complex

inhibitor tocilizumab are used as secondary therapies for moderate to severe RA when
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traditional DMARD therapy has not sufficed. As observed with in vivo models, both of
these cytokine targets mediate mechanical hypernociception as precedents to
prostanoids in the inflammatory stimuli-induced cytokine cascade.55 Interleukin-1β, an
isoform of a family of eleven IL-1 cytokines, is responsible for producing the most potent
pro-inflammatory effect. Its alpha isoform has also been implicated in inflammatory
pathologies; however, its particular role in RA has not been well-characterized. In RA,
IL-1β is released primarily by monocytes and macrophages as well as by nonimmune
cells, such as fibroblasts and endothelial cells. It was fairly recently discovered that IL1β is expressed in nociceptive dorsal root ganglion (DRG) neurons,56 and therefore its
upregulation could contribute to the experience of pain in RA. Moreover, IL-6 is found
in abundance in the synovial fluid and serum of RA patients, and there is a direct
relationship between its levels and disease severity.57

Anakinra, a recombinant human IL-1 receptor antagonist, blocks the activity of
both IL-1α and IL-1β. In a very recent review article compiling the outcomes from the
safety profile, clinical trials, observational studies, and registry data of anakinra,58 it has
been concluded that this drug is marginally used for the treatment of RA. It exhibits
lower efficacy compared with other biologic DMARDs, and its administration route of
daily subcutaneous injections has greatly limited its patient adherence.

From the data of numerous clinical trials,59–62 tocilizumab is the first agent
(biologic or otherwise) shown to be superior to MTX as monotherapy for the clinical
manifestations of RA. It is also effective in combination with MTX or other DMARDs.
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1.2.4.3

T-cell activation and CD20 activity inhibitors
In Phase II clinical trials with abatacept for the treatment of RA,63,64 biomarker

analysis revealed a reduction in RF; in C-reactive protein (CRP), which has a direct
correlation with pain sensitivity in RA; in soluble IL-2 receptor and IL-6; in TNF-α, also
involved in the generation and maintenance of inflammation-related pain; and in matrix
metalloproteinase-3 (MMP-3), among others. Inhibition of T-cell activation is consistent
with such decreased levels of these distinguishing factors in the pathogenesis of RA.
Double-blind follow-up studies of both Phase II and Phase III trials65 indicate large
improvements in disease activity, pain, and physical function in patients non-responsive
to MTX therapy, and comparable therapeutic efficacies to anti-TNF-α DMARDs in over
10% of patients receiving abatacept therapy.

Rituximab operates by destroying both malignant and normal B cells with surface
expression of CD20, allowing subsequent generation of healthy B cells from lymphoid
stem cells. Therefore, the medication has been used not only to treat autoimmune
disorders such as RA, but cancers of the leukocyte system, including leukemias and
lymphomas.66 B cells themselves are the source of RFs and anti-citrullinated protein
antibodies, which, as mentioned previously, contribute to immune complex formation
and complement activation in RA.

Moreover, B cells respond to and produce

chemokines and cytokines that stimulate many RA symptoms, such as angiogenesis
and synovial hyperplasia, all direct or indirect contributors to the pain involved.67

Each of these biologics introduced here can cause immune suppression to
varying degrees, sometimes more severely than that with traditional DMARDs.68 Side
effects include site injection reactions and immunogenicity, along with a variety of
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serious infections. Coupled with the harsh side effects that all of these genetically
engineered drugs can cause, their cost of production results in high prescription
expenses as well.

A recent cost effectiveness analysis has found that replacing

conventional DMARD therapy with biologics when MTX monotherapy fails yields only
minimal benefit compared to triple therapy using the traditional DMARDs sulfasalazine,
hydroxychloroquine, and MTX.69 This advantage is also largely not detected by the
patients. Thus, according to studies like these, more promising results for the symptoms
and progression of RA may be achieved with the use of conventional DMARDs as part
of a multi-therapy program.

1.2.5

Opioids
Opioids are a class of agonist ligands derived from the opium poppy plant either

extracted from the plant directly or synthesized as analogues. They are known to act
upon the ubiquitous opioid receptors; namely, the mu isoform (µOR) is their primary
target for analgesia, but to an extent their interactions with kappa and delta opioid
receptors have been demonstrated to contribute to pain relief as well.70 Though their
superior analgesic effects versus other, more mild painkillers such as NSAIDs has been
more and more frequently argued against, opioids have nonetheless been prevalently
used for complete suppression of non-malignant pain such as that with arthritis.
According to Curtis, et al.,71 40% of patients with RA were prescribed opioids regularly
in the average rheumatologist's practice. Some of these most commonly prescribed
opioids include hydrocodone, oxycodone, hydromorphone, oxymorphone, morphine,
codeine, and fentanyl.72 Endogenous opioids are produced by neurons, namely, betaendorphin, met- and leu-enkephalins, and dynorphins that act as neurotransmitters and
neuromodulators and provide analgesia.73 Inflammation of tissue leads to upregulation
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of opioid receptors and to local production of these peptides in immune cells.74 Yet due
to the often promiscuous action of extracellular peptidases,75 among a myriad of other
factors, the analgesia provided by these compounds is limited. The drug counterparts
to these neuropeptides act at the same receptor sites to produce measurable analgesic
effects. The outcomes of opioid receptor interactions are diverse, entailing exhaustive
cause-effect relationships that have a plethora of effects within the body.
Mechanistically, opioids and their endogenous neuropeptides phosphorylate and
dissociate their eponymous G-protein coupled receptors into their subunits, which bind
to and deactivate the voltage-gated calcium channel, preventing calcium ion influx. This
causes a reduction in pain-eliciting neurotransmitter release, as calcium is an essential
component of this process.76 Concurrent activation of the cell membrane’s G-proteincoupled inwardly-rectifying potassium (GIRK) channel increases potassium ion
conductance from the neuron, inducing membrane hyperpolarization.77 This inhibits
action potentials by increasing the stimulus required to move the membrane potential to
the action potential threshold, and therefore decreases neuronal excitability. Together
these interactions attenuate the pain response. Opioid receptors exist ubiquitously on
nerve cells involved in both the central and peripheral nervous systems. Particularly,
within the CNS, opioid receptors are expressed on neurons involved in the descending
pain-modulating pathways in several discrete yet widely interconnected areas of the
brain, and their activation serves to directly inhibit spinal cord pain transmission via
neuron inhibition.

Concern has been mounting over the past several decades in regard to the
escalating issue of opioid misuse when medicating for conditions beyond that of
temporary severe acute pain or chronic pain linked with active cancer or at the end of
life. According to a report from the Center for Disease Control and Prevention (CDC),
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there was a 300% increase in opioid sales from 1999 through 2010, and overdose
deaths in this period increased fivefold for women and 3.6 times for men.78

The

tendency for this drug class to encourage its abuse, and in some cases to ultimately
cause death, is related to its effects within the CNS. Here, a primary area that is acted
upon by opioids is that of the mesolimbic, or midbrain, reward center.

Neuronal

activation catalyzes the cascade that ultimately produces the neurotransmitter
dopamine.76 Dopamine is widely known to be responsible for the sensation of pleasure
and incentive salience, or “wanting”. Its synthesis and release within the brain provides
a euphoric effect.25 Dopaminergic neurons, which originate from the ventral tegmental
area (VTA) and project to several forebrain regions including the nucleus accumbens
(NAc, which has a significant role in the cognitive processing of reward), are relatively
few in number (~400,000 in the human brain),79 but their neuromodulatory
characteristics allow them to influence diverse populations of neurons. The mechanisms
by which opioids activate the reward pathway and contribute to reinforcement are
extremely complicated and debatable to date. The general consensus is that there are
three types of neurons which participate in opiate action: the dopamine terminal, another
terminal containing a different neurotransmitter, most likely gamma-aminobutyric acid
(GABA, an inhibitory neurotransmitter), and the post-synaptic cell containing dopamine
receptors. Opioids bind to their receptors on the neighboring terminal and this sends a
signal to the dopamine terminal to release more dopamine. One theory proposed is that
this receptor activation decreases GABA release, therefore allowing accumulation of
dopamine.36 This in turn generates reinforcement wherein the opioid user may become
dependent on the drug to provide feelings of gratification from positive feedback. Other
common physical side effects of opioids, which are primarily caused by their CNS
effects, include sedation, heart palpitations, dizziness, nausea, vomiting, and
constipation.80 Drug tolerance and addiction can ultimately relinquish the user’s mental
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and physical control, requiring higher doses, and therefore more potent side effects, to
gain the same analgesic effect. Extremely high doses can cause respiratory depression
and death.81 Additionally, severe withdrawal symptoms can occur if treatment is abruptly
ceased.80

There have been recent developments with opioids to render them specifically
peripherally-targeting, and therefore to limit the undesirable CNS effects. This has been
demonstrated with hydrophilic compounds, since they have limited capacity to cross the
BBB. Such examples include the mu-agonist loperamide, traditionally prescribed as an
antidiarrheal, and the kappa-agonist asimadoline. Other agents that have demonstrated
peripheral restriction are those of candidates with specific chemical modifications, such
as glucuronides and an arylacetamide, as well as peptide compounds.74 According to
studies in murine models,82 inflammatory hyperalgesic conditions, like that of RA, seem
to be especially amenable to the antinociceptive capabilities of peripheral opioids,
suggesting that multiple mechanisms of analgesia are at play.

Local injections of

otherwise systemically-inactive quantities of various opioid agonists produced dosespecific analgesia, and positive effects were also observed in models of nerve damage,
viscera, and cancer pain.83 Nonetheless, these improved CNS outcomes can still afford
further adaptations to specifically target the site of pain, rendering less off-target effects
than with peripherally-selective small molecule opioids themselves.

1.2.6

Antidepressants
Recent focus has been directed towards the use of mood enhancers such as

selective serotonin reuptake inhibitors (SSRIs) and selective inhibitors on both serotonin
and norepinephrine (NE) uptake (SNRIs) to treat pain and inflammation in RA. Dually-
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acting tricyclics (TCAs), which are first generation antidepressants so named for their
three-ring structures, may also have similar effects on arthritic pain. Accumulating
evidence has linked the biological substrates involved in mood disorders with
inflammatory conditions.84

By moderate estimates, around 13-17% of RA patients

exhibit symptoms of major depressive disorder.85 According to meta-analyses of clinical
studies, depressed patients have higher blood concentrations of IL-6 and TNF-α
compared with controls.86,87 Those with depression also report having more intense pain
and less control over their own everyday lives. In general, they may experience greater
interference from pain, and they often display more pain-related behaviors than those
chronic pain patients without depression. While some assert that the therapeutic effects
of antidepressants for RA and other inflammatory disorders are debatable at best, there
may be associations worth further exploration.

Serotonin, or 5-hydroxytryptamine (5-HT), is a monoamine neurotransmitter
mainly found in the enteric nervous system within the gastrointestinal tract, where it acts
to regulate intestinal movements. Within the brain, 5-HT is synthesized by serotonergic
neurons and regulates mood, appetite, and sleep.88 The drug class known as SSRIs
specifically inhibits the reabsorption of released 5-HT in the CNS. One of the primary
sites on which SSRIs act is that of the serotonin transporter (SERT), which regulates
serotonergic transmission. In preclinical studies,89 it has been shown that both the
density and activity of SERTs are upregulated by proinflammatory cytokines like TNF-α.
This in turn increases 5-HT uptake from the neural synapse and therefore decreases its
transmission.

The therapeutic potential of SSRIs for RA management has been

recognized in pre-clinical studies as well.

For example, the SSRIs fluoxetine and

citalopram significantly inhibited disease progression in murine collagen-induced arthritis

21

(CIA) models, and both drugs greatly suppressed the spontaneous production of TNF-α
and IL-6 in human RA synovial membrane cultures.88

Antidepressants with the dual action of inhibiting both 5-HT and NE uptake are
at times the preferred treatment in conditions of neuropathic pain. Norepinephrine, also
known as noradrenaline, is a catecholamine neurotransmitter of the sympathetic
nervous system that is released by the adrenal medulla as part of the fight-or-flight
response. There are several conjectures of NE’s relationship to mood regulation based
on supporting evidence.90

Norepinephrine projections innervate the limbic system,

which is implicated in the regulation of mood and biological instincts. Studies on mice
with NE transporter-knockout mice have shown lack of stress-induced depression
behaviors otherwise apparent in wild-type mice, while depletion of this neurotransmitter
from the brain has caused a return of depressive symptoms after successful treatment
with exogenous NE drug formulations.91,92 When released from the locus ceruleus of
the brain as part of the sympathetic nervous system response, NE has been evinced to
primarily downregulate inflammation via mechanisms on the innate immune system.93
Concerning their antinociceptive properties, placebo-controlled studies for the painalleviating efficacy of antidepressants in patients with RA revealed positive outcomes in
63.6% of those given dually-acting TCAs.94 However, the use of TCAs is waning due
to peripheral side effects as a result of their anticholinergic properties.95 A number of
SNRIs have had variable success in treating inflammatory pain.

One of the most

prominent examples, duloxetine, an SNRI under the trade name Cymbalta, has
demonstrated effective analgesic outcomes for chronic pain associated with
fibromyalgia and osteoarthritis (OA).96 Support for its use in RA, however, has yet to be
established.
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1.3

Strategies to improve PK/BD of pharmacological entities for RA pain
The short biological half-lives and poor bioavailabilities of the various RA

medications necessitate frequent and often high dosings. This in turn leads to toxicity and
side effects in extra-articular tissues. In RA, inherent pathophysiological attributes include
neoangiogenesis of vessels with disordered architecture and increased permeability. To
facilitate arthritic tissue targeting of anti-inflammatory and analgesic drugs, they can be
introduced into carrier systems that passively target the inflamed lesions via the leaky
vasculature. These modes of drug transport also prevent premature clearance from the
body and aid in minimizing toxicities of their cargo. Additionally, the prodrug approach
can be enacted to ensure drug activation solely within the site of infection.

1.3.1

Macromolecular arthrotropism and synovial retention in inflammatory

joints
The pathophysiology of inflammation shares many of the same traits as the
enhanced permeability and retention, or EPR, effect that prevails in tumor tissue. By
this particular mechanism can large molecules, i.e. serum proteins and other
macromolecules, accumulate within the tumor mass more so than they would in normal,
healthy tissue. This phenomenon is generally interpreted as a stratagem that tumors
possess to promote cancer growth and metastasis. Attributes contributing to the EPR
effect include angiogenesis through stimulation of vascular endothelial growth factor
(VEGF) and other growth factors, and dependence of tumor cell aggregates on the blood
supply carried by this neovasculature. This vessel architecture is often disordered and
abnormal, with poor alignment of endothelial cells and large fenestrations between the
cells that account for the leakiness of macromolecules and other nanoparticulate
systems.97 The inflamed tissues of RA and other inflammatory diseases maintain many
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of these same qualities. Preliminary studies have proven the ability of serum proteins
and macromolecules to preferentially extravasate to areas of increased vasculature in
animal models of inflammation. In one particular pilot study within our lab,98 Evans blue,
an azo dye that has high affinity for serum albumin, was intravenously injected in a rat
model of adjuvant-induced arthritis (AIA) affecting the ankles. Sustained presence of
the blue color within the joint synovial tissues of the inflamed ankles can be ascribed to
the vasculature leakage associated with articular inﬂammation.99,100 However, unlike in
tumor tissue, the lymphatics responsible for the generation and maintenance of immune
responses undergo normal or even accelerated drainage in the diseased joints of
arthritis models, presumably as part of the regulation of the peripheral inflammatory
status through extrinsication of cells and fluid.101 Therefore, supporting studies102 have
been done to ascertain the mechanisms involved in the arthrotropism and sustained
retention of macromolecules. It was discovered through immunohistochemical (IHC)
and fluorescence-activated cell sorting (FACS) analyses of AIA rats that fluorescentlylabeled macromolecules resided within type A synoviocytes (macrophage-like) and type
B synoviocytes (fibroblast-like). This Extravasation through Leaky Vasculature and
subsequent Inﬂammatory cell-mediated Sequestration, collectively coined the ELVIS
mechanism, still requires further research to probe its various components. Additional
data from our laboratory using several different animal models of inflammation103–107
feature similar trends in the targeting and retention abilities of various macromolecular
drug carriers, suggesting that ELVIS is a generalized strategy for large molecules as a
whole.
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1.3.1

Drug carriers to target inflamed synovium
Modern medical research has generated a wide array of biocompatible materials

from which to choose when designing and creating strategies for targeted drug delivery
in RA. For any given disease, a candidate for improved drug pharmacokinetics and
biodistribution (PK/BD) ideally shields it from rapid clearance by the mononuclear
phagocytic system (MPS, aka the reticuloendothelial system or RES), prolonging the
circulation half-life; prevents drug effects at off-target locations in an effort to minimize
toxicity; and can preferentially release the pharmaceutical entity at the intended site for
maximum therapeutic benefit. Many of the contenders for targeted delivery include
chemotherapeutics as their payload, but since tumor pathophysiology shares many
similarities with arthritic tissue, it can be presumed and has been proven in some cases
that these systems can also be effective in conditions such as RA. To date, the research
into macromolecular scaffolds for drug delivery in inflammatory ailments such as RA
includes primarily liposomal formulations, polymeric nanoparticles (NPs), and linear
platforms such as N-(2-hydroxypropyl)methacrylamide (HPMA)-based copolymers.
These strategies have been tested with variable success to improve the tissue delivery
and medical benefit of therapeutic agents.

1.3.1.2

Liposomes
One of the most exploited and well-documented vehicles for drug delivery is that

of the liposome. These are biodegradable bilayered phospholipid vesicles encasing an
aqueous core, capable of entrapping both hydrophilic and hydrophobic molecules. At the
dawn of their research as pharmaceutical excipients, their effectiveness was limited by
rapid in vivo clearance.108 This bottleneck has since been resolved through attachment of
poly(ethylene glycol), or PEGylation, onto the liposome surface, forming a hydration layer
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that hinders protein adsorption and therefore reduces opsonization in blood circulation
that would prime the liposomes for MPS clearance. Several liposomal formulations have
been designed and utilized clinically for cancer treatment. USFDA-approved liposomes
include doxorubicin (Dox)-loaded Doxil®/Caelyx® approved for AIDS-related Kaposi's
sarcoma, recurrent ovarian cancer, metastatic breast cancer and multiple myeloma,109
and Myocet® for metastatic breast cancer.110 Marqibo®, a vincristine-loaded excipient,
has also been approved for use in lymphoblastic leukemia.111 Many other formulations
are currently or have been investigated in Phase I, II, and III clinical trials.112

The

application of this technology has also been explored in the diagnosis and treatment of
other inflammatory maladies like RA. Liposome intravenous (i.v.) administration in several
animal models of RA has yielded promising results, particularly in studies with Dex, MTX,
and prednisolone as the payload.113

When designing a liposomal drug delivery system, several caveats must be
considered. Cationic liposomes used primarily for glycoprotein interaction for enhanced
cellular uptake and DNA binding in gene delivery have been shown to induce Type I and
II interferon responses.114 Anionic liposomes, exploited for their increased endocytosis
within phagocytic cells, can activate the complement system and induce hypersensitivity
reactions.115 Even neutrally-charged formulations with a cholesterol content of over 30
mol% can activate the classical complement pathway. This is due to the presence of both
IgG and IgM type anticholesterol antibodies, abundant in mammalian sera as part of a
‘housekeeping’ or protective role for the host animal against toxic forms of cholesterol
such as low-density and very-low-density lipoproteins (LDL and VLDL).116 Another welldocumented occurrence is that of the generation of anti-PEG IgM antibodies after first
exposure to PEGylated NP systems in animal models.117

The emergence of these

antibodies in the human population is collectively due to cumulative exposure to PEG-
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containing cosmetics, pharmaceuticals, and processed food products. This has resulted
in loss of therapeutic effect through accelerated liposomal clearance following repeated
dosings, and even adverse events, such as reduced tolerance and immunogenic
responses including anaphylaxis and infusion reactions, have been disclosed.118

1.3.1.3

Polymeric nanoparticles
Many of the polymer-based NPs used in RA are formulated using poly(D,L-lactic-

co-glycolic acid) (PLGA). This amphiphilic polymer has attracted considerable attention
due to its biodegradability and surface modification potential, as well as its ability to
encapsulate both hydrophobic or hydrophilic small molecules or macromolecules. It has
been approved by the USFDA and by the European Medicine Agency as drug delivery
systems for parenteral administration.119 Both passive targeting via the EPR effect and
active targeting ligands have been utilized as means of chemotherapeutic drug delivery
for PLGA-based NP systems.

For instance, in a murine model of subcutaneously

implanted B-cell lymphoma, PEGylated PLGA NPs encapsulating Dox enhanced antitumoral efficacy compared to the free drug alone.

This formulation also drastically

decreased the cardiomyopathies often seen with Dox treatment, with even better results
compared to the liposome formulation Doxil.120 Many other PLGA formulations with
doxorubicin feature the inclusion of a folate targeting moiety. One study in particular has
demonstrated both higher cellular uptake and more potent cytotoxicity in in vitro and in
vivo studies of endometrial cancer cells.121

However, the EPR effect is highly

heterogeneous and varies amongst tumor types, and the introduction of targeting moieties
onto the NP surface often leads to immunogenicity and protein adsorption. In models of
inflammatory arthritis, PLGA NPs are uptaken by the MPS and have been shown to
preferentially accumulate at the arthritic lesions. In different animal arthritis models,
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accumulation of betamethasone sodium phosphate-loaded PLGA-PEG NPs within the
inflamed synovium was achieved through either direct intra-articular or systemic injection,
with sustained drug release resulting in prolonged therapeutic efficacy.122 Yet despite the
encouraging data from PLGA-based nanoparticulate systems, their often low drug loading
capability, high production costs, and difficult scale-up implementations have constrained
them from further development into the clinic.119

Another popular group of synthetic NP-assembling polymers for drug delivery in
inflammatory diseases is distinguished by their highly symmetric, monodisperse design.
Known as dendrimers, these macromolecules have a densely-packed shell morphology
consisting of repeating branch units with terminal functional groups. Their reproducibility,
multivalent structure, and supramolecular properties have rendered them as excellent
nanocarriers for drug molecules. For cancer therapy, various nucleic acid as well as small
molecule formulations have evinced great potential. For example, an arginine-modified
polyamidoamine (PAMAM) dendrimer complexed with the human interferon beta (IFN-β)
gene demonstrated induction of apoptosis and significant tumor reduction in a mouse
model of xenograft brain tumor.123 Several dendrimer polyplexes with chemotherapeutics
such as Dox and paclitaxel have also had such success in models of breast, pancreatic,
and lung cancers.124–127 While cancer treatment has been the main focus of these drug
delivery vehicles, their anti-inflammatory capabilities have also been delved into. It was
recently serendipitously discovered that dendrimers alone without inclusion of any
pharmaceutical excipients can evoke anti-inflammatory responses, and particularly
PAMAM dendrimers have been most often used in investigations into this phenomenon.
Upon unveiling their anti-inflammatory effects, Chauhan, et al. synthesized and tested the
efficacy of empty PAMAM dendrimers with both amine and hydroxyl terminal groups.128
Assessment of the NPs on lipopolysaccharide (LPS)-induced nitric oxide (NO) and COX-
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2 activities in rat peritoneal macrophages showed maximum inhibitory effects compared
to carboxylic acid-terminated controls, and these same dendrimers exhibited antiinflammatory activities in both carrageenan- and adjuvant-induced models of arthritis.
Another group has taken advantage of the upregulated expression of folate receptor-β on
activated macrophages to design a both actively- and passively-targeted dendrimer
system. They verified the superior therapeutic benefits of folate receptor-targeted MTXconjugated PAMAM dendrimers versus free MTX in AIA rats.129 Mechanistic insights into
dendrimer antirheumatic activity, however, are currently limited and require extensive
research to validate whether they indeed provide advantages in treating RA over other,
conventional therapies. In addition, each class of dendrimer has shown cytotoxic and
hemolytic properties,130 which raises concerns over toxicity and may not bode well
especially for therapeutic drug delivery in inflammatory diseases like RA.

1.3.1.4

HPMA copolymers
The advent of different polymeric scaffolds besides NP-forming constituents such

as PAMAM or PLGA for drug delivery has taken shape over the past several decades.
Generally, the hydrodynamic size of these types of polymeric conjugates (>10 nm) favors
less premature MPS uptake even when compared to PEGylated nanocarriers.131
Conjugation of drugs directly onto the backbone or the branches of these carriers
eliminates the problem of untimely drug leakage that adversely affects the desired
pharmacokinetics, as is commonly seen with liposomal formulations. Since the 1960s,
the research of the Jindřich Kopeček laboratory has concentrated on biomedical watersoluble polymers based on hydrophilic esters and N-substituted amides of methacrylic
acid. Polymeric HPMA (pHPMA) was chosen for further studies, owing to its ease of
synthesis and reproducibility.132 It has been validated to be biocompatible, since its
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homopolymer was not recognized as a foreign macromolecule in vivo, and no
immunogenicity was detected.133,134 Various HPMA-based copolymer conjugates were
also proven to cause minimal activation of the complement system.135 In addition, the
branched architectures allow for maximum constituent loading per molecule, in contrast
to linear polymeric scaffolds such as PEG. Early work involving HPMA nanocarrier
structures was often tailored to chemotherapeutic drug delivery. The first polymer-drug
conjugate to enter into clinical trials was that of the HPMA copolymer-Dox conjugate in
1999,135 followed by investigations with HPMA copolymer conjugates of other anticancer
agents such as paclitaxel and camptothecin.136,137 While the clinical success of HPMA
copolymers seems clear, the first marketed product is still awaited and therapeutic indices
of these drug platforms must be optimized. Furthermore, HPMA copolymers have been
validated to target the inflamed synovium in murine models of inflammatory arthritis,
unveiling another potentially clinically relevant use for these drug scaffolds. In a pilot study,
copolymers labeled with an MRI contrast agent, DOTA/GD3+, were intravenously
administered to AIA rats and exhibited arthrotropism within 1 hr of injection. Signal was
tightly retained in the inflammatory region even up to 48 hr, versus healthy controls from
which all signal was diminished within 8 hr.98 Recent work in the Dong Wang laboratory
has ventured forward to show preferential targeting and accumulation of HPMA-based
nanocarriers in rodent models of inflammatory arthritis, as well as sustained retention of
these macromolecules within the site of interest.98,102,138,139

1.3.3

Acid-labile linker between drug and macromolecule backbone
Once a macromolecular entity such as an HPMA copolymer has reached the

inflamed synovium of the arthritic joint, it must release its drug payload via a local
stimulus that is present in the pathology of RA. It has long since been discovered140 that
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the synovial fluid in arthritic joints maintains increased levels of lactic acid, contributing
to the pH decrease often associated with these conditions. Low partial oxygen pressure,
or hypoxia, is a constant feature of RA. As synovial inflammation progresses, small
venules, which are vessels in the microcirculation that allow blood to return from the
capillary beds to drain into the veins, become occluded by hypertrophied endothelial
cells, platelets, fibrin, and inflammatory cells. Thus, circulation into synovial tissue is
compromised. Under these conditions, a key regulator of responsive mechanisms to
adapt to such low oxygen environments is that of hypoxia-inducible factor (HIF)-1α. This
transcription factor drives anaerobic catabolism within the arthritic synovium and
synovial fluid, elevating the production of lactic acid and pyruvate, as well as abnormal
angiogenesis and amassment of growing tissue, or pannus formation, in the diseased
joints.141 The pH value of synovial fluid within arthritic joints have been reported to be
as low as 6.0,142 with values ranging from 4.4-5.6 in synovial tissue itself.143 Therefore,
to control the releasing rate of drugs conjoined to macromolecular platforms which target
to inflamed areas, it logically follows to take advantage of this pathophysiological factor
by introduction of an acid-labile linker between the analgesic drug and polymer.

There are several acid-sensitive chemical linkers that have been explored in
drug-polymer conjugates, especially in the selective delivery of chemotherapeutic
agents to tumor tissue, which often have lower extracellular pH values. For instance,
Dox has been conjugated to HPMA via acid-cleavable linkages such as aconityl,144
polyacetal,145 and hydrazone.146 Classically, such drug-polymer conjugates had been
established with enzyme-sensitive peptide moieties, most often glycyl-phenylalanylleucyl-glycine (GFLG),147,148 that would be cleaved upon entrance into cellular lysosomal
compartments containing proteases such as cathepsin B, which is intracellularly
overexpressed in a variety of metastatic and invasive cancers. Initial in vitro studies
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found that the acid-labile HPMA-Dox conjugates, namely those with hydrazone,149
elicited anti-proliferative activities on T-cell EL4 lymphoma cells at a much greater
potency than those conjugates with enzyme-activated linkers. The pH-labile prodrugs
can therefore bypass the need for the presence of lysosomal enzymes at the target site,
and can rather release their active pharmaceutical components by mild acid hydrolysis
within the endosomal compartments. The hydrazone bond, moreover, has been found
to be relatively stable in buffers at neutral pH (7.4), which mimics the conditions of blood
circulation.150

For inflammatory disorders such as but not limited to arthritis, our

laboratory has previously studied copolymer conjugates of HPMA and Dex with
hydrazone linkers.138,151 It was found through in vitro release profiles that there are
indeed much higher rates of drug cleavage within more acidic buffers.

In vivo

experiments have further verified drug activation within the inflamed regions after
systemic injection in murine models of inflammatory diseases, suggesting that similar
outcomes can be achieved with HPMA copolymers including analgesic therapies as their
cargo.

1.3

Summary
The chronic inflammatory conditions present in RA cultivate both neuropathic and

nociceptive manifestations of pain. While RA cannot be cured at present, there are
many different types of USFDA-approved medications that are prescribed at the onset
and/or for the duration of the disease to ease its symptoms and slow its progression.
There exists a complex relationship between inflammation and pain that renders these
types of drugs useful in lessening the pain that is inevitably present with this polyarticular
ailment. Each drug has been verified for its pain-alleviating capabilities both in vitro and
in vivo, with some more clinically-developed than others. However, the free drugs alone
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ordinarily lack tissue specificity and are rapidly cleared from the body due to their
recognition by the mononuclear phagocytic system (MPS). This generally necessitates
frequent, high-dose administration schedules, eliciting dangerous and sometimes fatal
side effects if certain precautionary measures are not enacted.

In particular,

dexamethasone (Dex), an immunosuppressive GC medication, is one of the most highly
effective substances used for controlling the inflammatory response and consequent
pain in patients with RA, but comorbidities such as diabetes and osteoporosis can
develop. Additionally, opioid medications such as hydromorphone (HMP) have been
prescribed for serious cases of chronic pain, as with that in RA, yet their effect within the
CNS has implicated them in the generation of neurological disorders such as tolerance
and addiction. To offset these disadvantages, modern research has provided a virtual
nanomedicine toolbox from which we can formulate strategies to effectively enhance the
PK/BD parameters of existing drugs. Previously, in our lab, it has been validated that a
macromolecular

Dex

conjugate

based

on

the

biocompatible

N-(2-

hydroxypropyl)methacrylamide (HPMA) copolymer (P-Dex) can selectively target and be
retained at the inflammatory lesions present in murine models of RA, improving the
therapeutic outlook of the GC medication. The ultimate goal of this project, therefore, is
to reevaluate and further test the analgesic properties of the Dex prodrug. Moreover,
development of another macromolecular system based on HPMA should be able to
selectively deliver HMP, a commonly-prescribed opioid for pain relief, to the multiple
sites of inflammation responsible for the generation of pain effectors present in the
pathology of RA, with the added benefit of possibly mitigating the CNS effects often
evident with opioid use.

In this thesis, the first hypothesis is that both P-Dex and the opioid-conjugated
HPMA (P-HMP) display arthrotropic capabilities via passive targeting to the inflammatory
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lesions in a monoarticular inflammatory arthritis rat model compared to healthy nonarthritic controls. Second, it should be apparent that there is sustained retention of
these acid-cleavable prodrugs within the joint synovia and associated tissues, due to
phagocytic uptake by inflammatory immune cells such as FLS and macrophages.
Following this, the third conjecture to be tested is whether these two prodrugs can
significantly enhance the overall therapeutic efficacies compared to equivalent doses of
the free drugs alone.
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CHAPTER 2
HPMA COPOLYMER-BASED DEXAMETHASONE FOR THE TREATMENT
OF ARTHRITIC PAIN AND INFLAMMATION

2.1 Introduction
As outlined in the previous chapter, RA is characterized by often widespread
arthrous synovial inflammation and pain.

Within the arthritic joints, hyperplasia is

coupled with the influx of immune cells that contribute to the ultimate destruction of the
surrounding articular matrix, ultimately resulting in bone erosion and joint deformity.
GCs are potent anti-inflammatory agents that not only suppress immune responses, but
inhibit the two primary products of inflammation, i.e. leukotrienes and PGs. Since there
is a complex interplay between these immune cells and lipid mediators and the extant
nociceptive pathways within the arthritic joint, their contribution to the experience of pain
within RA is also modulated with the use of GCs. However, because these drugs
frequently cause off-target toxicity, they are often used in combination with DMARDs
until the disease activity is largely under control. Additionally, in severe cases of RA,
patients may need to continue treatment with GCs indefinitely to alleviate pain and
inflammation.

To ameliorate the symptoms of RA, to date there have been developed several
formulation and conjugation strategies to facilitate the targeting of drugs to arthritic joints
and to enhance the pharmacodynamic properties of these antirheumatics.

As

mentioned previously, our own laboratory has developed and characterized an acidlabile arthrotropic macromolecular dexamethasone (Dex) prodrug based on N-(2hydroxypropyl)methacrylamide (HPMA), known as (P-Dex). A single dose of a Dex-
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conjugated HPMA copolymer was able to ameliorate joint inflammation for up to twenty
days in a rat adjuvant-induced arthritis (AIA) model, reinforcing HPMA as the vehicle of
choice in further studies investigating improved drug delivery of antirheumatic and
analgesic drugs.139 These exceptional remedial characteristics of macromolecular HPMA
prodrugs are due to a phenomenon termed ELVIS, i.e. Extravasation through Leaky
Vasculature and Inflammatory cell-mediated Sequestration, exploited to selectively
localize and retain therapeutic agents at the inflammatory sites present in many chronic
conditions. In light of the superior therapeutic results of P-Dex on inflammation within
the AIA rat, we have sought to determine the improved analgesic properties of this
prodrug as well, versus free Dex controls using the same rodent disease model.

2.2 Materials and methods
2.2.1 Materials
N-(3-Aminopropyl) methacrylamide (APMA) hydrochloride was purchased from
Polysciences, Inc. (Warrington, PA). N-(2-Hydroxypropyl) methacrylamide (HPMA)152
and S,S′-bis(α,α′-dimethyl-α″-acetic acid)-trithiocarbonate (CTA, purity >97%)153 were
prepared as reported previously.

Dexamethasone (Dex) sodium phosphate was

purchased from Hawkins Pharmaceutical Group (Minneapolis, MN). IRDye® 800CW
carboxylate was purchased from LI-COR Biosciences (Lincoln, NE). Alexa Fluor® 488
NHS ester was purchased from Life Technologies, Inc (Eugene, OR). All other reagents
and solvents were purchased from either Sigma-Aldrich (St. Louis, MO) or Acros
Organics (Morris Plains, NJ). All compounds were reagent grade and used without
further purification.
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2.2.2 Instruments
1

H and 13C NMR spectra were recorded on a 500 MHz NMR spectrometer (Varian

Medical Systems, Palo Alto, CA). Mass spectrum analyses were performed with a
LC/MS/MS system consisting of an ACQUITY Ultra Performance LC (UPLC) system
(Waters Corporation, Milford, MA) and a Sciex 4000 Q TRAP mass spectrometer with
an electrospray ionization (ESI) source (Applied Biosystems, Toronto, Canada).
Chromatographic separations were carried out on a C18 column (Waters Corporation;
100 x 2.1 mm; 1.7 µm; flowrate 0.3 mL/min; mobile phase A: 5% ACN in MeOH, mobile
phase B: 7.5 mM ammonium acetate, pH 6.0; 45% A:55% B). The weight average
molecular weight (Mw) and number average molecular weight (Mn) of copolymers were
determined by size exclusion chromatography (SEC) using an AKTA Pure FPLC system
(GE Healthcare, Chicago, IL) with a DAWN 8+ multi-angle static light scattering (MALS)
detector for absolute molecular weight measurements and an Optilab T-rEX
refractometer for RI detection (Wyatt Technology Corporation, Santa Barbara, CA,
USA). SEC separations were performed on a Superdex 200 column (HR 10/30) with
phosphate-buffered saline (PBS, pH 7.4) as the eluent. HPMA homopolymer samples
with narrow PDI (polydispersity index) values were used as calibration standards. High
performance liquid chromatography (HPLC) analyses were performed on an Agilent
1100 HPLC system (Agilent Technologies, Inc., Santa Clara, CA) with a reverse phase
C18 column (Agilent, 4.6 × 250 mm, 5 µm).

Spectrophotometric absorbance

measurements were performed using a SpectraMax M2e UV/Vis spectrophotometer
(Molecular Devices, Sunnyvale, CA). Bone microarchitectures were evaluated using a
SkyScan 1172 micro-CT system (SkyScan, Kontich, Belgium).

Semiquantitative

biodistribution studies were carried out using an IVIS® Spectrum in vivo imaging system
(PerkinElmer, Inc., Waltham, MA).

The near-infrared ex vivo organ analysis was
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accomplished using a Pearl® Impulse small animal imaging system (LI-COR
Biosciences, Lincoln, NE). A Faxitron® MX-20 Cabinet X-ray System (Faxitron Bioptics,
LLC, Tucson, AZ) was used for detection of the decalcification progress. A Leica
RM2255 microtome (Leica Biosystems, Buffalo Grove, IL) was used for paraffinembedded tissue sectioning. For fluorescent microscopic analysis, tissue sections were
evaluated using a Zeiss LSM 800 confocal microscope (Carl Zeiss Microscopy,
Thornwood, NY).

Static hind paw weight bearings were evaluated on an Incap

incapacitance meter (Columbus Instruments, Columbus, OH).

2.2.3 Synthesis of poly(HPMA-co-Dex) (P-Dex)
2.2.3.1 Synthesis of N-methacryloylglycylglycyl hydrazide (MA-Gly-Gly-NHNH2)
N-methacryloylglycylglycine (MA-Gly-Gly-OH, 0.8 g, 4 mmol) was suspended in
ethanol (15 mL, 0°C), and to this was added the inhibitor (tert-octyl pyrocatechine) to
prevent spontaneous polymerization. N,N′-dicyclohexylcarbodiimide (DCC, 0.9 g, 4.4
mmol) in ethanol (5 mL) was then added to this reaction solution. The mixture was stirred
for 2 h at 0°C and 2 h at rt, then subsequently filtered to remove dicyclohexylurea (DCU).
Hydrazine hydrate (0.4 mL) in ethanol (5 mL) was then added into the filtrate and the
solution was stirred for 4 h at rt. Upon precipitation of crystalline material, hexane (25 mL)
was added and the final product was filtered and washed with a mixture of ethanol and
hexane (1:1, v/v).

1

H NMR (500 MHz, d6-DMSO) δ (ppm): 8.94 (s, 1H), 8.15 (t, J = 5.6

Hz, 1H), 8.07 (t, J = 5.6 Hz, 1H), 5.74 (s, 1H), 5.38 (s, 1H), 3.75 (d, 2H), 4.20 (s, 2H), 3.75
(d, J = 5.8 Hz, 2H), 3.66 (d, J = 5.3 Hz, 2H), 1.88 (s, 3H); 13C NMR (125 MHz, d6-DMSO)
δ (ppm): 169.7, 168.5, 168.2, 139.9, 120.3, 42.9, 41.3, 19.0.
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2.2.3.2 Synthesis of pH-sensitive, Dex-containing monomer (MA-Gly-Gly-NHN=Dex)
MA-Gly-Gly-NHNH2 (214 mg, 1 mmol) and Dex sodium phosphate (392 mg, 1
mmol) were dissolved in methanol (10 mL). Acetic acid (0.5 mL) was added to the reaction
solution as a catalyst. The solution was purged with argon and stirred for 3 days at rt in a
sealed ampule. After evaporation of the reaction solvent, the product was purified by flash
column chromatography (DCM:MeOH = 10:1, v/v).

1

H NMR (500 MHz, d6-DMSO) δ

(ppm): 10.90 (s, 0.6 H), 10.50 (s, 0.4 H), 8.22-8.18 (m, 1 H), 8.12 (s, 0.4 H), 7.89 (t, J =
5.0 Hz, 0.6 H), 6.98 (dd, 51.0, 10.0 Hz, 0.4 H), 6.80 (s, 0.4 H), 6.64 (dd, 25.5, 11.0 Hz, 0.6
H), 6.45 (dd, J =15.5 Hz, J = 10.0 Hz, 0.6 H), 6.25 (dd, J= 24.0 J = 10.0 Hz, 0.6 H), 6.01
(d, J = 22.0 Hz, 0.4 H), 5.75 (s, 1 H), 5.39 (s, 1 H), 5.15 (s, 1 H), 4.94 (s, 1 H), 4.68 (s, 1
H), 4.48 (dd, J =19.5 Hz, J =5.5 Hz, 1 H), 4.14 (d, J = 4.0 Hz, 1 H), 4.07 (dd, J =19.0 Hz,
J = 5.5 Hz, 2 H), 3.87 (s, 1 H), 3.78 (dd, J =15.0 Hz, J = 6.0 Hz, 02 H), 2.94 (m, 1 H), 2.642.61 (m, 1 H), 2.31-2.24 (m, 2 H), 2.18-2.12 (m, 2 H), 1.74-1.67 (m, 1 H), 1.61-1.57 (m, 1
H), 1.42 (d, J = 5.0 Hz 3 H), 1.33-1.24 (m, 3 H),1.07-1.05 (m, 1H), 0.85 (s, 3 H), 0.82 (d,
J = 7.0 Hz, 3 H); 13C NMR (125 MHz, d6-DMSO) δ (ppm): 211.7 (two isomers), 170.8 (two
isomers), 169.9 & 169.7 (two isomers), 168.2 &168.1 (two isomers), 165.9 & 165.8 (two
isomers), 157.7 & 157.3 (two isomers), 151.8 & 146.7 (two isomers), 144.4 & 144.2 (two
isomers), 143.4 & 139.9 (two isomers), 139.8 & 139.3 (two isomers), 126.9 & 126.8 (two
isomers), 120.8 & 116.9 (two isomers), 120.3 &116.9 (two isomers), 101.8 (d, JCF = 173
Hz) & 101.4 (d, JCF = 173 Hz) (two isomers), 90.7 & 90.6 (two isomers), 70.5 (d, JCF = 37
Hz) &70.2 (d, JCF = 37 Hz) (two isomers), 66.8 & 47.9 (two isomers), 47.8 (d, JCF = 22 Hz)
& 47.6 (d, JCF = 22 Hz) (two isomers), 43.9 & 42.8 (two isomers), 42.9 & 42.8 (two isomers),
41.8 & 40.9 (two isomers), 36.4 & 36.3 (two isomers), 35.4 & 32.5 (two isomers), 34.8 &
30.9 (two isomers), 34.4 (d, JCF = 20 Hz) & 34.2 (d, J = 20 Hz) (two isomers), 31.3 & 31.2
(two isomers), 27.5 (two isomers), 24.6 (d, JCF = 6 Hz) & 24.3 (d, JCF = 6 Hz) (two isomers),
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19.0 & 19.0 (two isomers), 17.1 (two isomers), 15.8 &15.7 (two isomers). Diastereomers
were chromatographically separated using LC/MS/MS. Mass spectra (negative ion ESI)
were analyzed for C30H41FN4O7: [M-H]- calculated: 587.3; found: 587.3. This confirms their
monoisoptopic mass of 588.3.

2.2.3.3 Synthesis of Dex-containing HPMA copolymer conjugate (P-Dex)
The P-Dex copolymer was synthesized via a reversible addition-fragmentation
chain transfer (RAFT) polymerization method adapted from previous work. To a 10-mL
glass ampule was added HPMA (400 mg, 2.79 mmol), MA-Gly-Gly-NHN=Dex (116 mg,
0.20 mmol), AIBN initiator (4.26 mg, 0.03 mmol), and the RAFT agent CTA (4.16 mg,
0.02 mmol), then the components were dissolved in 4 mL methanol. The mixture was
purged with argon (5 min) and flame-sealed, then allowed to react under magnetic
stirring (48 hrs, 60 °C). The resulting product (P-Dex) was purified using an LH-20 silica
gel column with methanol as the mobile phase. The purified product was evaporated of
solvent, then transferred to a 20-mL glass scintillation vial and frozen (-80 °C, 2 hrs)
prior to lyophilization (48 hrs).
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Scheme 2.1 Synthesis of HPMA copolymer-dexamethasone (Dex) conjugate (P-Dex).
CTA, chain transfer agent; AIBN, 2,2’-azobisisobutyronitrile; MeOH, methanol.
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2.2.4 Synthesis of dye-containing P-Dex conjugates
2.2.4.1 Synthesis of poly(HPMA-co-Dex-co-APMA)
To a glass ampule was added HPMA (400 mg, 2.79 mmol), MA-Gly-Gly-Dex (117
mg, 0.20 mmol), 2,2′-azobisisobutyronitrile (AIBN, 4.37 mg, 0.03 mmol), RAFT agent S,S′bis (α, α′-dimethyl-α″-acetic acid)-trithiocarbonate (CTA, 4.17 mg, 0.02 mmol), and APMA
(5.48 mg, 0.03 mmol), dissolved in 4 mL methanol. The mixture was purged with argon
(5 min) and flame-sealed. The solution was allowed to react under magnetic stirring (48
hrs, 60 °C). The resulting product (P-Dex-APMA) was purified using an LH-20 silica gel
column with methanol as the mobile phase. The purified product was evaporated of
solvent, then transferred to a 20-mL glass scintillation vial and frozen (-80 °C, 2 hrs) prior
to lyophilization (48 hrs).

2.2.4.2 Synthesis of poly(HPMA-co-Dex-co-IRDye 800CW) (P-Dex-IRDye)
Into a glass vial was placed P-Dex-APMA (170 mg, containing 0.0154 mmol
APMA), EDCI (29.6 mg, 0.154 mmol), HOBt (23.4 mg, 0.154 mmol), DIPEA (19.9 mg,
0.154 mmol), and IRDye 800CW carboxylate (1 mg, 0.0009 mmol), dissolved in DMF
(2mL). The mixture was stirred in darkness (16 hrs, rt). The resulting products was
purified using an LH-20 column and subsequently lyophilized.

2.2.4.3 Synthesis of poly(HPMA-co-Dex-co-Alexa Fluor 647 (P-Dex-Alexa)
Into a glass vial was added P-Dex-APMA (170 mg, containing 0.0154 mmol
APMA), DIPEA (19.9 mg, 0.154 mmol), and Alexa Fluor 647 NHS ester (1 mg, 0.0016
mmol), dissolved in DMF (2 mL). The mixture was stirred in darkness (16 hrs, rt), and
product was purified using an LH-20 column and subsequently lyophilized.
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2.2.5 Characterization of P-Dex and fluorescent analogs

The drug contents of all three products (P-Dex, P-Dex-IRDye, P-Dex-Alexa) were
determined via HPLC after hydrolysis (0.1 M HCl, 2 mg/mL, 72 hrs) and neutralization (0.1
M NaOH) using a mobile phase of acetonitrile:water 30:70 (v/v), with UV detection at 240
nm and a flowrate of 1 mL/min. The Dex content was measured in triplicate and compared
against a range of standards of the dexamethasone base in methanol. Dye contents of
the dye-labeled prodrugs were determined using UV/Vis spectrophotometry with several
dilutions of the prodrugs in DI water.

2.2.6 Establishment of monoarticular arthritis model
Male Lewis rats (175-200 g) were obtained from Charles River Laboratories and
allowed to acclimate for at least one week under standard housing conditions. Freund’s
complete adjuvant was freshly prepared by mixing methylated bovine serum albumin
(mBSA, 2 mg/mL) in distilled water with Mycobacterium tuberculosis strain H37RA (2
mg/mL) in paraffin oil to form an emulsion. Rats were injected with adjuvant (0.5 mL)
subcutaneously (s.c.), twice at two different sites on the back during a one-week interval
for immunization. After an additional two weeks, animals were anesthetized (1-1.5%
isoflurane and O2) and given an intraarticular injection of mBSA (500 μg in 50 μL distilled
water) to the left knee joint cavity to induce monoarticular AIA. Successful establishment
of arthritis was confirmed by the presence of edema in the left hindlimbs and of the rats’
compromised gaits.

All animal experiments were carried out in accordance with

guidelines evaluated and approved by the Institutional Animal Care and Use Committee
(IACUC) of the University of Nebraska Medical Center.
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2.2.7 In vivo near-infrared P-Dex biodistribution study in AIA rats
The day after arthritis induction, rats (n = 8) were administered a mixture of PDex-IRDye (IRDye equivalent 3.5 x 10-7 mol/kg) and P-Dex (altogether 10 mg/kg Dex
equivalent) via tail vein injection. Rats were imaged using the IVIS Spectrum imaging
system on days 1, 3, 7, 10, 14, and 21 to evaluate distribution and retention of the IRDyelabeled prodrug. Prior to acquisition, rats were anesthetized (2% isoflurane and O2) and
hair was removed from the hindquarters to avoid attenuation of fluorescence signal.
Captured images were then analyzed using the Living Image 4.5 software (PerkinElmer,
Inc.). On days 1, 3, and 21, rats (n = 3 per group) were perfused intracardially with
saline and fixed with 4% (w/v) paraformaldehyde (PFA) in saline. Vital organs and
hindlimbs were dissected and visualized for fluorescence intensities using the Pearl
Impulse near-infrared imager with a dual-channel acquisition (800 nm and white light) at
85 µm resolution. All images from each instrument were normalized to equivalent
minimum and maximum intensity values.

2.2.8 Immunohistochemical analysis of P-Dex
To AIA rats was intravenously injected P-Dex-Alexa (Dex equiv. 10 mg/kg, n =
3) one day post-induction. On day 1 post-dosing, rats were perfused intracardially with
saline, then fixed with 4% (w/v) PFA in saline. The hind limbs were collected then
decalcified using 20X specimen volume of freshly-prepared neutralized 10% (w/v) EDTA
solution. The decalcifying solution was changed daily in the first week, then three times
a week, until complete removal of calcium was confirmed via X-ray. Each tissue sample
was then cut to size directly around the joint and synovial areas and then paraffinembedded. Slices (20 µm) were cut using a microtome and placed onto tissue-adherent
slides. After antigen retrieval using sodium citrate buffer and blocking using 10% normal

45

goat serum, the slides were incubated separately with mouse anti-rat CD68 (Bio-Rad,
MCA341R, dilution 1:100) or rabbit anti-rat P4HB (ProSci Inc., 8213, dilution 1:100).
Additionally, rats from saline-treated and P-Dex-treated groups were perfused 21 days
post-dosing and the left hindlimb knee joints were used for paraffin IHC staining with
rabbit anti-rat COX-2 antibody (Novus Biologicals, NB100-689SS, dilution 1:100). Right
hindlimb knee joints from these groups were also paraffin-embedded and stained for
COX-2 expression. All slides were allowed to incubate overnight at 4°C. Slides were
then treated with goat anti-rabbit Alexa Fluor 568 (dilution 1:1000) or goat anti-mouse
Alexa Fluor 568 (dilution 1:1000) at room temperature in the dark (1 hr). The stained
slides were imaged using a ZEISS LSM 800 confocal microscope after mounting in
ProLong® Gold antifade mountant with DAPI (Thermo Fisher Scientific, P36931).

2.2.9 Histological analysis of inflammation in joint tissue
To AIA rats was administered P-Dex (10 mg/kg equiv. Dex), Dex 4X i.v.
(dexamethasone sodium phosphate in saline, 2.5 mg/kg daily, 4X), Dex 10X i.v.
(dexamethasone sodium phosphate in saline, 1 mg/kg daily, 10X), or saline. Hind limbs
were decalcified using either 20X specimen volume of freshly-prepared 4% (w/v) formic
acid. Tissues were monitored until complete removal of calcium was confirmed via Xray analysis. Each tissue sample was then cut to size directly around the joint and
synovial areas and then paraffin-embedded. Slices (8 µm) were cut using a microtome
and placed onto tissue-adherent slides. Successive slices from each block were stained
with either hematoxylin and eosin (H & E) or safranin-O. The stained sections were
imaged by a pathologist (SML), who was blind to the treatment groups.
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2.2.10 Evaluation of bone quality using micro computed tomography
Diseased and healthy rat hind limbs were collected after euthanasia and fixed
with buffered formalin for at least 48 h prior to evaluating the knee joint microarchitecture
parameters using a Skyscan 1172 micro-computed tomography (micro-CT) system.
Micro-CT scanning parameters were as follows: voltage, 70 kV; current, 142 μA;
exposure time, 3650 ms; resolution, 12.99 μm; with aluminum filter (0.5 mm); rotation
step (deg) = 0.400; frame averaging = 6; random movement = 10; using 360° rotation
scanning. Raw images were reconstructed using NRecon (Skyscan) to obtain a visual
representation of the results, and the volume rendering of the samples was performed
by CTvox software (Skyscan). To quantitatively compare the four treatments, the femur
of the left hindlimb was identified as the anatomical site for micro-CT analysis. Using
the CT-Analyzer (CTAn) software, trabecular bone from each sample was selected for
analysis based on a polygonal region of interest (ROI) within the center of the femur,
beginning at 40 slices proximal from the growth plate and extending proximally 60 slices
further. The right hindlimbs were also analyzed as a positive control with no arthritis
induction. Several morphometric parameters of subchondral trabecular bone directly
above the epiphyseal plates, such as bone volume (BV, mm3), bone volume fraction
(BV/TV, %), trabecular thickness (Tb.Th, μm), trabecular separation (Tb.Sp, μm), and
trabecular number (Tb.N, 1/mm), were calculated using CTAn (Skyscan).

2.2.11 Analgesic and inflammation-ameliorating efficacy study
Dex 4X i.v. (2.5 mg/kg daily, n = 6), Dex 10X i.v. (1 mg/kg daily, n = 6) or P-Dex
(Dex equiv. 10 mg/kg, n = 6) were administered to AIA rats by tail vein injection (i.v., 1
mL/kg). Saline was injected intravenously as a control (n = 6). The weight distribution
between the animal’s hind limbs was measured using the incapacitance tester. Animals
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were placed on the incapacitance tester with their hind paws centered on the two force
transducers, and the average body weight distribution in grams was calculated over a
period of three seconds. The weight bearing score is expressed as a ratio of the weight
placed through the limb ipsilateral to the inflammation versus the sum of the weights
placed through both the contralateral and ipsilateral limbs, with a ratio of 50% resulting
from equal weight distribution across both hind limbs. Weight distribution was measured
before induction, before dosing, and at several time intervals following drug
administration, up to twenty-one days. The mediolateral diameters of the left and right
hindlimbs were also measured using a digital Vernier caliper.

2.2.12 Statistical methods
Data are shown as mean ± SD. Statistical analysis was performed using Prism
version 7.03 (GraphPad Software, Inc.). The results were analyzed using two-way
ANOVA, and individual groups were compared using Tukey’s HSD test for multiple
comparisons.

2.3 Results
2.3.1 Synthesis and characterization parameters of P-Dex prodrugs
All three Dex-conjugated HPMA copolymers were successfully synthesized and
characterized. Since the selected strategies had already been proven in our laboratory
to yield consistently uniform polymers with narrow dispersities, the synthetic methods
were undergone efficiently with little difficulty.

Therefore, it was expected that the

copolymer conjugates of Dex would exhibit consistent results with relatively uniform
dispersities, indicative of well-controlled reactions which produce a homogenous size
distribution of copolymers (Table 2.1).
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2.3.2 Near-infrared biodistribution and retention study of P-Dex in AIA rats
Significant fluorescent signal of the P-Dex-IRDye is evident even at 21-days postdosing (Figure 2.1). The panel offers a clear visual representation of the tendency of
this macromolecular prodrug to accumulate and be retained at areas of inflammation.
While increased vascular permeability allows the P-Dex to preferentially target the
inflamed knee joint, sequestration by local phagocytic cells is largely responsible for the
the prodrug’s maintained residence within the synovial cavity.

Organs harvested at days 1, 3, and 21 post-dosing were analyzed for their
relative fluorescence intensities and clearly demonstrate not only the prodrug’s targeting
to the diseased anatomical location, but its distribution in the kidneys as well. The
PK/BD parameters of P-Dex and its renal clearance mechanisms have been wellestablished.104,154 By twenty-one days post-dosing, contrary to the arthritic joint, the
kidney fluorescent signal had almost completely diminished (Figure 2.2). This reflects
the rapid bodily elimination of the off-target portion of the prodrug.
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Figure 2.1 Near-infrared biodistribution analysis at post-injection time points of P-Dex
prodrug within the arthritic knee joint. Each panel represents the same animal
throughout the imaging process. Signal intensities are normalized to the same values
in all images.
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Figure 2.2 Ex vivo organ and limb fluorescence of P-Dex at 1 day, 3 days, and 21 days
post-dosing. Ht, heart; Ln, lungs; Kd, kidneys; Sp, spleen; Lv, liver; Rt, right leg; Lt, left
leg.

52

2.3.3 Analysis of P-Dex, inflammatory immune cells, and inflammatory marker
cellular distribution within synovium
There is distinct co-localization of P-Dex (magenta) with the CD68 signal
(macrophage marker, green, panel A, Figure 2.3) as well as a small portion with P4HB
(fibroblast marker, red, panel B, Figure 2.3) in the paraffin slides derived from the
ipsilateral knee joints of AIA rats. The nuclei are indicated by DAPI staining (blue).
Additionally, COX-2 upregulation is evident in the immune cells of the saline-treated
arthritic synovium (Figure 2.4 B), while its expression is greatly reduced in the cell
population of the synovia and synovial tissue from the heathy (Figure 2.4 C) and P-Dex
(Figure 2.4 D) groups.
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Figure 2.3 Representative confocal fluorescence microscopy images of inflammatory
cells co-localized with P-Dex copolymer within the synovium of the arthritic knee joints
1 day post-dosing. Top, from left to right: P4HB (fibroblast); P-Dex; DAPI; merged.
Bottom, from left to right: CD68 (macrophage); P-Dex; DAPI; merged. All scale bars = 20
µm.
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Figure 2.4 Representative confocal fluorescence microscopy images of COX-2
expression within the synovium of A) healthy, B) saline-treated, and C) P-Dex-treated
knee joints 21 days post-dosing. From left to right: COX-2; DAPI; merged. All scale bars
= 20 µm.
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2.3.4 Histological analysis of inflamed tissue in P-Dex-treated AIA rats
The representative micro-CT images clearly delineate bone destruction in both
the saline and Dex 4X i.v. treatment groups (Figure 2.5).

Both groups feature

amassment of cells within the bone, and the representative image from the saline group
further illustrates synovial lining cell hyperplasia alongside damaged cartilage.
However, the P-Dex-treated group remains the most similar in bone morphology
compared with stained sections from the healthy group. The representative image of
the healthy limbs, here represented by a safranin-O slide, further accentuates the intact
cartilage in that particular group, a characteristic which can also be visualized in the PDex H & E slide.
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Figure 2.5 Representative histological images of synovium and surrounding bone from
select treatment groups. A) Safranin-O image of healthy synovium indicating intact
cartilage and normal bone. B) H&E slide illustrating P-Dex treatment and its bone and
cartilage protective effects. C) H&E image of saline treatment, indicating cellular
infiltration (*), bone destruction (single arrow), and synovial cell lining hyperplasia (double
arrow). D) H&E image representative of the Dex high dose group, showing cell
proliferation within the bone and loss of bone integrity.
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2.3.5 Bone joint quality assessment
The left femur from each animal was assessed for its morphometric parameters
via micro-CT quantitative evaluation of trabecular bone distal to the growth plate (Figure
2.6).

It is clearly evident by analysis of various morphometric indices that P-Dex

treatment most efficiently preserves bone quality, followed by Dex 10X i.v., and Dex 4X
i.v., respectively. The P-Dex group values of bone volume fraction (BV/TV), bone
surface density (BS/TV), bone mineral density (BMD), trabecular number (Tb.N), and
trabecular separation (Tb.Sp) are all most similar to the healthy control group. The
quantitative analysis data of femoral trabecular bone is corroborated by the
representative grayscale reconstructed images from each treatment group (Figure 2.7).
The most severely eroded trabecular bone belongs to the saline-treated group. The Dex
4X i.v. treatment group also displays significant bone destruction at twenty-one days
post-initial dosing. However, Dex 10X i.v. treatment for ten consecutive days seems to
garner protection of bone tissue appreciably beyond the interval of Dex administration.
Moreover, as has been proven in our previous studies, the single dose treatment of PDex affords minor bone loss after three weeks, and is most similar in quality to the noninduced healthy (right) femurs.
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Figure 2.6 Micro-CT morphometric analyses demonstrating the quantitative indices
associated with femoral trabecular bone from each treatment group. Data are
expressed as mean ± SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Figure 2.7 Representative reconstructed micro-CT images along the basic anatomical
planes of femoral bone from each treatment group.
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2.3.6 Analgesic and anti-edema efficacy of P-Dex in AIA rats
The mean weight distribution ratio (percent weight bearing score, %WBS) was
calculated for each group using the following formula:

𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑛 𝑖𝑛𝑗𝑢𝑟𝑒𝑑 𝑙𝑒𝑔
%𝑊𝐵𝑆 = &
6 ∗ 100
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑛 𝑢𝑛𝑖𝑛𝑗𝑢𝑟𝑒𝑑 𝑙𝑒𝑔 + 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑛 𝑖𝑛𝑗𝑢𝑟𝑒𝑑 𝑙𝑒𝑔

The WBS values (Figure 2.8) from the single-dose P-Dex animals remained the most
similar to pre-induction values for the duration of the study. For the daily-injection free
Dex groups, incapacitance values followed course with the P-Dex group. Interestingly,
the scores for the Dex 4X i.v. group descended below those of the saline negative
controls merely one day after cessation of the injection intervals, while the Dex 10X i.v.
group exhibited a similar trend, albeit several days after discontinuation of the daily
injections.

Limb size measurements (Figure 2.9) closely correlated with the weight bearing
scores of their respective treatment groups. The saline control group did not exhibit any
significant signs of improvement in limb swelling for the three weeks measured.
However, edema was decreased to approximately baseline measurements in the free
Dex groups for the duration of the treatment, while the P-Dex group showed steadily
controlled values close to those of the pre-induction timepoint.
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Figure 2.8 A) Percent weight bearing scores (%WBS, or incapacitance) of AIA rats.
B) Statistical significance levels of %WBS versus each treatment group over the time
course measured (in days). *, P < 0.05 vs. Saline; **, P < 0.01 vs. Saline; ***, P < 0.001
vs. Saline; ****, P < 0.0001 vs. Saline; †, P < 0.05 vs. Dex High; ††, P < 0.01 vs. Dex High;
†††, P < 0.001 vs. Dex High; ‡, P < 0.05 vs. Dex Low; ‡‡, P < 0.01 vs. Dex Low; ‡‡‡, P
< 0.001 vs. Dex Low; ‡‡‡‡, P < 0.0001 vs. Dex Low; #, P < 0.05 vs. P-Dex; ##, P < 0.01
vs. P-Dex; ###, P < 0.001 vs. P-Dex; ####, P < 0.0001 vs. P-Dex.
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Figure 2.9 A) Change in left (ipsilateral) knee joint diameter in AIA rats. B) Statistical
significance levels of arthritic limb size changes versus each treatment group over the
time course measured (in days). *, P < 0.05 vs. Saline; **, P < 0.01 vs. Saline; ***, P <
0.001 vs. Saline; ****, P < 0.0001 vs. Saline; †, P < 0.05 vs. Dex High; ††, P < 0.01 vs.
Dex High; †††, P < 0.001 vs. Dex High; ‡, P < 0.05 vs. Dex Low; ‡‡, P < 0.01 vs. Dex
Low; ‡‡‡, P < 0.001 vs. Dex Low; ‡‡‡‡, P < 0.0001 vs. Dex Low; #, P < 0.05 vs. P-Dex;
##, P < 0.01 vs. P-Dex; ###, P < 0.001 vs. P-Dex; ####, P < 0.0001 vs. P-Dex.
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2.4 Discussion
Therapies for RA pain remain ever-evolving in search of strategies to render
current drugs more efficacious with improved safety profiles.

In particular,

glucocorticoids (GCs) are still currently used to quell the immune response culpable in
the onset and progression of RA.

Through their various molecular targets and

mechanisms of action can the inevitable pain involved in the disease be largely
alleviated. Yet the off-target toxicities of these free drugs alone are an insurmountable
issue that must be addressed by development of formulation or synthetic approaches to
modify the PK/BD profiles of such medicines. The pathological traits of RA itself can be
taken advantage of to tailor a prodrug system which preferentially targets the arthritic
lesions and provides therapeutic effect at the inflammatory sites.

The water-soluble synthetic polymer HPMA is one of the most extensively
studied drug carriers, and has been chosen as the platform to which a model GC, Dex,
was conjugated. The prodrug’s superior therapeutic and safety profiles have been
validated in several animal models of inflammatory diseases.104–107,138,154,155

As an

addendum to the established effect on murine models of RA, the analgesic impact of
this Dex prodrug strategy was studied. Articular bone erosion as largely prompted by
the synovitis which occurs in RA is one of the most predictive measures of disease
course and disability, and is directly correlated to mortality.156 This synovitis responsible
for bone deterioration is moreover one of the direct causes of the severe pain present in
patients with RA. In addition, cartilage erosion can directly cause joint pain itself through
bone-on-bone contact. Through measures of the morphometry and the preservation of
the bone and surrounding periarticular structures, we have shown that P-Dex is superior
to free Dex in its therapeutic benefits. Its mechanisms of action on pain are varied,
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through cartilage preservation, edema taming, cytokine suppression, and COX-2
downregulation. This strategy not only serves as beneficial to bone microarchitecture,
which in itself is not painful, but has the dual purpose of alleviating pain through joint
preservation and quiescence of proinflammatory mediators.

As seen in the near-infrared biodistribution analysis with P-Dex, the copolymer
preferentially targets the inflamed site of the arthritic knee joint. This supports findings
that enhanced vascular permeability in inflammatory conditions is conducive to the
transport of macromolecules such as HPMA. The sustained fluorescent signal up to 21
days post-dosing is due to the internalization by activated immune cells within the
inflamed synovium, as concluded previously.138 In this thesis, IHC analyses have also
suggested that the prodrug is uptaken and retained within these two cell types, as is
especially evident in the immunohistofluorescent image illustrating macrophage and
drug co-localization. Organ fluorescence analysis further ascertained the uptake of the
P-Dex copolymer within the kidneys, where it undergoes glomerular filtration and rapid
bodily excretion. The quickly-degrading kidney fluorescent signal coincides with prior
pharmacokinetic studies involving HPMA-based copolymers.

Our P-Dex prodrug has been proven in AIA models to preserve bone
microarchitecture and to dampen the inflammatory immune response that contributes to
overall joint degradation.102,139 It is clear from these most recent histochemical and
morphometric analyses that the left hindlimbs from P-Dex-treated rats are most similar
in quality to healthy controls. Interestingly, the free Dex 10X i.v. treatment exhibited
better results than the Dex 4X i.v. treatment group. In humans, abrupt withdrawal from
GCs has been known to cause regressive disease flare-ups, steroid withdrawal
syndrome, or adrenal insufficiency, in which atrophy of the adrenal glands themselves
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occurs.157 As the most potent GC analogue, Dex itself has a prolonged biological effect
of 36-54 hours upon administration, and thus produces the greatest suppression on the
HPA axis.158 Moreover, systemic administration of free Dex results in significantly higher
suppression than with other routes, such as intraarticular injection or inhalation. Without
gradual tapering to allow recovery to homeostatic baseline hormone levels, Dex
withdrawal may involve symptoms of either the primary disease itself or a secondary
syndrome, dependent on the dosage and duration of administration.

These drug

characteristics may partially explain why the Dex 4X i.v. group exhibits poorer bone
structural integrity and more pronounced inflammatory features within surrounding
tissue versus the Dex 10X i.v. group. As seen in the histological images, the Dex 4X i.v.
group has aggressive accumulation of polymorphonuclear cells within the bone and
synovial lining, as is often observed in the acute stages of inflammation, further
illustrating the relapse into arthritic conditions after discontinuation of free drug
administration. It should be noted that the trabecular thicknesses amongst all groups
are not significantly affected by treatment regime. This needs to be further explored to
elucidate why this parameter does not change. The values for the diseased group are
expected to be significantly lower than at least the P-Dex and healthy control groups,
conforming to the results many other studies involving the AIA model.159–161 Aside from
this, the incapacitance studies comply with the results from the micro-CT and
histochemical analyses. The rapid, sub-negative control drop in average weight bearing
scores for the Dex 4X i.v. group upon ending treatment is perhaps reflective of disease
exacerbation that can occur if therapy is abruptly stopped, through mechanisms still not
fully understood.

It was moreover qualitatively verified that P-Dex indeed has a

downregulative effect on the production of COX-2 in the IHC findings. The more intense
fluorescence indicative of COX-2-positive cells within the synovial tissues of the
untreated rats versus the P-Dex-treated group could indirectly illustrate the pain-
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alleviating capabilities of our copolymer via its inhibition of COX-2 protein and steadystate mRNA expression. The resulting reduction in prostaglandin synthesis is one of the
mechanisms through which it is known that GCs can provide pain relief in inflammatory
diseases such as RA. Additionally, a seemingly decreased cell population and differing
cell morphologies in the P-Dex knee joint versus the saline-treated group suggest an
inhibitory effect by the prodrug on inflammatory infiltrates.

2.5 Conclusion
Through preferential arthritic lesion targeting and gradual activation within the
synovium, a single i.v. injection of our P-Dex displayed superior antinociceptive and antiinflammatory effects compared to multiple doses of the free drug alone.

Previous

studies within our laboratory have confirmed P-Dex’s ability to diminish inflammatory
symptoms while also maintaining bone protection from the mediators of inflammation in
a rat model of AIA. In this study, while the therapeutic effects of free Dex were primarily
sustained only throughout the actual dosing days, it was found that P-Dex significantly
improved not only the inflammatory symptoms associated with the AIA model mimicking
RA, but the resulting pain that is present in the arthritic conditions as well.
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CHAPTER 3
HPMA COPOLYMER-BASED HYDROMORPHONE FOR THE TREATMENT OF
ARTHRITIC PAIN

3.1 Introduction
The use of opioids for the treatment of both acute and chronic pain has been
practiced for thousands of years.162 Opioids modulate nociception, the sensory nervous
system’s response to potentially harmful stimuli, through direct agonist action on opioid
receptors, which are ubiquitous within the CNS and reside at the peripheral terminals of
afferent nerves.70,74

These ligands act to inhibit neurotransmitter release in primary

afferent terminals in the spinal cord and activate descending inhibitory controls, giving rise
to their analgesic effect. Opioids are relatively safe when used correctly and with caution.
However, long-term opioid use has been proven controversial.163–166 Mechanistically,
these compounds act directly on the brain’s natural reward system to beget dopamine,167
which produces a euphoric effect. Drug tolerance characterized by neuroadaptations and
physical dependence can thus transition into addiction if not well-controlled. Therefore,
the safe clinical use of opioid necessitates the mitigation of these undesired CNS effects.

Synthetic water-soluble polymers such as those based on HPMA cannot permeate
the blood-brain barrier (BBB),168 but they have been found to target inflammation in several
animal models of human diseases.104,106,107,138 We therefore hypothesized that upon
systemic administration of an opioid-conjugated prodrug system in a rat model of
monoarticular AIA, the prodrug can preferentially extravasate through vascular leakage
present in the arthritic joints and be sequestered by residential and infiltrated inflammatory
cells that have been activated by inflammatory cytokines and possess high rates of
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endocytosis.

The internalized prodrug will be processed in the acidic lysosomal

compartments, releasing the opioid and promoting local analgesic effects.

In this chapter, we report the design and synthesis of an HPMA copolymer
conjugate of hydromorphone (HMP), a semi-synthetic opioid receptor agonist, which is
estimated to be five to ten times more potent than morphine.169 Marketed under the brand
name Dilaudid, this narcotic analgesic has been in clinical use since the 1920s to alleviate
a variety of painful conditions.170–173

Hydromorphone can produce neuroexcitatory

metabolites in addition to its potentially addictive qualities.174 In an effort to address
these issues, HMP has been chemically conjugated to the main chain HPMA copolymer
via an acid-labile hydrazone bond, much like in the design strategy of our P-Dex prodrug
outlined in the previous chapter. We here demonstrate the preferential inflammation
targeting ability of this macromolecular prodrug of HMP. Compared to the free drug, our
prodrug has been observed to significantly reduce the spinal cord analgesic effects,
suggesting its limited passage through the BBB. Thus, our synthetic strategy could be
especially beneficial by decreasing the adverse CNS events often seen with the use of
these narcotic analgesics.

3.2 Materials and methods
3.2.1 Materials
N-(3-Aminopropyl) methacrylamide (APMA) hydrochloride was purchased from
Polysciences, Inc. (Warrington, PA). N-(2-Hydroxypropyl) methacrylamide (HPMA),152
S,S′-bis(α,α′-dimethyl-α″-acetic
methacryloylglycylclycyl

acid)-trithiocarbonate

hydrazide

(CTA,

(MA-Gly-Gly-NHNH2),175

purity
and

>97%),153

poly

N-

(HPMA-co-

APMA)176 were prepared as reported previously. Hydromorphone (HMP) hydrochloride
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was purchased from Sigma-Aldrich (St. Louis, MO). IRDye® 800CW carboxylate was
purchased from LI-COR Biosciences (Lincoln, NE). Alexa Fluor® 488 NHS ester was
purchased from Life Technologies, Inc (Eugene, OR). All other reagents and solvents
were purchased from either Sigma-Aldrich (St. Louis, MO) or Acros Organics (Morris
Plains, NJ). All compounds were reagent grade and used without further purification.

3.2.2 Instruments
1

H and 13C NMR spectra were recorded on a 500 MHz NMR spectrometer (Varian

Medical Systems, Palo Alto, CA). The weight average molecular weight (Mw) and number
average molecular weight (Mn) of copolymers were determined by size exclusion
chromatography (SEC) using the ÄKTA FPLC system (GE Healthcare, Chicago, IL)
equipped with UV and RI (Knauer, Berlin, Germany) detectors. SEC measurements were
performed on a Superdex 200 column (HR 10/30) with phosphate-buffered saline (PBS,
pH 7.4) as the eluent. HPMA homopolymer samples with narrow PDI values were used
as calibration standards. HPLC analyses were performed on an Agilent 1100 HPLC
system (Agilent Technologies, Inc., Santa Clara, CA) with a reverse phase C18 column
(Agilent, 4.6 × 250 mm, 5 µm). Tail flick latencies were measured on an Ugo Basile Talk
Flick Unit (Ugo Basile SRL, Varese, Italy) and static hind paw weight bearings were
evaluated on an Incap incapacitance meter (Columbus Instruments, Columbus, OH).
Semiquantitative biodistribution studies were carried out using an IVIS® Spectrum in vivo
imaging system (PerkinElmer, Inc. Waltham, MA). A Faxitron® MX-20 Cabinet X-ray
System (Faxitron Bioptics, LLC, Tucson, AZ) was used for detection of the decalcification
progress. A Leica RM2255 microtome (Leica Biosystems, Buffalo Grove, IL) was used
for paraffin-embedded tissue sectioning.

For fluorescent microscopic analysis, both

cultured cells and tissue sections were evaluated using a Zeiss LSM 800 confocal
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microscope (Carl Zeiss Microscopy, Thornwood, NY). Spectrophotometric absorbance
measurements were performed using a SpectraMax M2e UV/Vis spectrophotometer
(Molecular Devices, Sunnyvale, CA).

3.2.3 Synthesis of poly(HPMA-co-HMP) (P-HMP)
HPMA (400 mg, 2.79 mmol) and MA-Gly-Gly-NHNH2 (41.9 mg, 0.196 mmol) were
dissolved in methanol (3 mL), and to this solution was added the initiator 2,2′azobisisobutyronitrile (AIBN, 2.37 mg, 0.0145 mmol) and RAFT agent S,S′-bis (α, α′dimethyl-α″-acetic acid)-trithiocarbonate (CTA, 2.27 mg, 0.008 mmol). The solution was
purged with argon and polymerized at 50 °C for 48 hr. The resulting polymer was first
purified on a LH-20 column (GE Healthcare, Waukesha, WI) to remove the unreacted low
molecular weight compounds and obtain the desired product. The resulting copolymer
(330 mg) and hydromorphone hydrochloride (33.5 mg, 0.11 mmol) were then dissolved in
methanol (3 mL). Acetic acid (0.3 mL) was added to the reaction solution as a catalyst.
The solution was again purged with argon and stirred at room temperature for 72 hr. After
evaporation of the reaction solvent, the P-HMP product was purified by LH-20 column.
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Scheme 3.1 Synthesis of HPMA copolymer-hydromorphone (HMP) conjugate (PHMP). CTA, chain transfer agent; AIBN, 2,2’-azobisisobutyronitrile; MeOH, methanol.
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3.2.4 Synthesis of poly(HPMA-co-HMP-co-APMA)
As the precursor to the dye-containing copolymers, poly(HPMA-co-HMP-coAPMA) was first synthesized. Briefly, HPMA (500 mg, 3.49 mmol), APMA (6.8 mg, 0.038
mmol), MA-Gly-Gly-NHNH2 (53 mg, 0.247 mmol), AIBN (2.98 mg, 0.018 mmol) and CTA
(2.38 mg, 0.01 mmol) were dissolved in methanol (6 mL) in a glass ampule. After purging
with argon for 5 min, the ampule was flame-sealed and heated at 50° C for 48 hr in the
absence of light. The mixture was then purified by LH-20 column to remove the unreacted
low molecular weight compounds, dialyzed (molecular weight cutoff = 25 kDa) for 24 hr in
ddH2O and then lyophilized. The resulting copolymer (300 mg) and hydromorphone
hydrochloride (32.3 mg, 0.1 mmol) were dissolved in methanol (3 mL). Acetic acid (0.3
ml) was added to the reaction solution as a catalyst. The solution was purged with argon
and stirred for 72 hr at room temperature. Upon evaporation of the reaction solvent, the
poly(HPMA-co-HMP-co-APMA) product was purified by LH-20 column.

3.2.5 Synthesis of poly(HPMA-co-HMP-co-IRDye 800CW) (P-HMP-IRDye)
Poly(HPMA-co-APMA-co-HMP) (150 mg, containing 0.0084 mmol amine) and
IRDye 800CW carboxylate (1 mg, 0.0009 mmol) were dissolved in dimethylformamide
(DMF, 300 μL) with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) activating
agent (13 mg, 0.084 mmol), hydroxybenzotriazole (HOBt, 11.3 mg, 0.084 mmol) and N,
N-diisopropylethylamine (DIPEA, 10.8 mg, 0.084 mmol).
overnight in darkness at room temperature.
purified via LH-20 column and lyophilized.

The mixture was stirred

Subsequently, the mixture was directly
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3.2.6 Synthesis of poly(HPMA-co-HMP-co-Alexa Fluor 488) (P-HMP-Alexa)
Poly(HPMA-co-APMA-co-HMP) (150 mg, containing 0.0084 mmol amine), Alexa
Fluor 488 NHS ester (1 mg, 0.0016 mmol) was dissolved in DMF (1 mL) and to the solution
was added DIPEA (10.8 mg, 0.084 mmol). The mixture was stirred overnight in darkness
at room temperature, immediately after which it was directly purified via LH-20 column and
lyophilized.
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Scheme 3.2 Synthesis of A) IRDye-containing HMP copolymer conjugates and B)
Alexa Fluor 488-containing HMP copolymer conjugate.
EDCI, 1-ethyl-3-(3dimethylaminopropyl)carbodiimide; HOBt, hydroxybenzotriazole; DIPEA, N, Ndiisopropylethylamine; DMF, dimethylformamide.
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3.2.7 Characterization of HMP-containing copolymer conjugates
The molar mass dispersities of the P-HMP copolymer and the corresponding dyelabeled conjugates were measured via SEC. To quantify the HMP content in all three PHMP copolymers, the conjugates (2 mg/mL) were hydrolyzed overnight in 0.1 N HCl. The
solutions were neutralized and analyzed on the HPLC system (mobile phase,
acetonitrile:water = 35:65; detection, UV 230 nm; ﬂow rate, 1 mL/ min; injection volume,
10 μL). Analyses were performed in triplicate. Dye contents of P-HMP-Alexa and P-HMPIRDye were analyzed at an OD of 494 nm and 774 nm, respectively, using three different
dilutions, each in triplicate, and measured using UV/vis spectrophotometry.

3.2.8 In vitro HMP release from P-HMP
The P-HMP conjugate (2 mg/mL) was dissolved in acetate buffers (0.01 M with
0.15 M NaCl, pH 5.0 and pH 6.5, respectively) or phosphate buffer (0.01 M with 0.15 M
NaCl, pH 7.4) and incubated at 37°C. At selected time intervals, aliquots (0.3 mL) were
withdrawn and neutralized, if appropriate, for HPLC analysis.

3.2.9 Cell culture study
RAW 264.7 cells were grown in a 75 cm2 flask to confluence in Dulbecco’s Modified
Eagle Medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS) and 1%
penicillin/streptomycin (100 U/mL and 100 µg/mL, respectively) under incubation (37 °C,
5% CO2).

Cells were scraped and their density counted using a hematocytometer

visualized under a light microscope, and the suspension was thereafter diluted (2´105
cells/ml) in fresh supplemented media. To a 24-well plate was added 15-mm diameter
round coverslips and suspension media (1 mL). The macrophages were allowed to
adhere onto the coverslips under incubation (24 hr, 37 °C, 5% CO2). The following day,
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coverslips were washed and aspirated (2´, PBS) and to each well was added LPS (10
µg/mL) in fresh, unsupplemented media, and cells were again incubated (24 hr, 37°C, 5%
CO2). The P-HMP-Alexa was then directly added to each well (final concentration 200
µg/mL) and placed under incubation (24 hr, 37 °C, 5% CO2). The following day, cells were
aspirated and washed (2´, PBS), and to the wells was added media with LysoTracker™
Red DND-99 (75 nM, Thermo Fisher Scientific, L7528). After incubation (3 hr, 37 °C, 5%
CO2), coverslips were washed and aspirated (2´, PBS), fixed, and mounted onto
microscope slides using the ProLong™ Gold Antifade mountant containing DAPI nuclear
stain (Thermo Fisher Scientific, P36931). Upon drying, the slides were immediately
visualized using confocal microscopy.

3.2.10 Establishment of a monoarticular AIA model
Male Lewis rats (175-200 g) were obtained from Charles River Laboratories and
allowed to acclimate for at least one week under standard housing conditions. Freund’s
complete adjuvant was freshly prepared by mixing mBSA (2 mg/mL) in distilled water with
Mycobacterium tuberculosis strain H37RA (2 mg/mL) in paraffin oil to form an emulsion.
Rats were injected with adjuvant (0.5 mL) subcutaneously (s.c.), twice at two different sites
on the back during a one-week interval for immunization. After additional two weeks,
animals were anesthetized (1-1.5% isoflurane and O2), and given an intraarticular injection
of mBSA (500 μg in 50 μL distilled water) to the left knee joint cavity to induce
monoarticular AIA. Successful establishment of arthritis was confirmed by the presence
of edema in the left hindlimbs and of the rats’ compromised gaits. All animal experiments
were carried out in accordance by guidelines evaluated and approved by the Institutional
Animal Care and Use Committee (IACUC) of the University of Nebraska Medical Center.
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3.2.11 Near-infrared biodistribution study of P-HMP in AIA rats
The day after arthritis induction, rats (n = 4 per imaging day) were administered a
mixture of P-HMP-IRDye (IRDye equivalent 3.5 x 10-7 mol/kg) and P-HMP (altogether 6
mg/kg HMP equivalent) via tail vein injection. Rats were imaged using the IVIS Spectrum
imaging system on days 1 and 3 to evaluate distribution and retention of the IRDye-labeled
prodrug. Prior to acquisition, rats were anesthetized (2% isoflurane and O2) and hair was
removed from the hindquarters to avoid attenuation of fluorescence signal. Captured
images were then analyzed using the Living Image 4.5 software (PerkinElmer, Inc.).

3.2.12 Immunohistochemical analysis of the knee joint
To AIA rats was intravenously injected P-HMP-Alexa (HMP equiv. 6 mg/kg, n = 12)
one day post-induction. On day 1 post-dosing, rats were perfused intracardially with
saline, then fixed with 4% (w/v) PFA in saline. The hind limbs were collected then
decalcified using 20´ specimen volume of freshly-prepared neutralized 10% (w/v) EDTA
solution. The decalcifying solution was changed daily in the first week, then three times a
week, until complete removal of calcium was confirmed via X-ray. Each tissue sample
was then cut to size directly around the joint and synovial areas and then paraffinembedded. Slices (20 µm) were cut using a microtome and placed onto tissue-adherent
slides. After antigen retrieval using sodium citrate buffer and blocking using 10% normal
goat serum, the slides were incubated separately with mouse anti rat CD68 (Bio-Rad,
MCA341R, dilution 1:100) and rabbit anti-rat P4HB (ProSci Inc., 8213, dilution 1:100).
Dually-stained slides were treated with antibodies for either guinea pig anti-rat µOR
(Novus Biologicals, NB100-1618, dilution 1:100) plus guinea pig anti-rat TRPV1
(RayBiotech, 114-10040, dilution 1:100) or with rabbit anti-rat PGP9.5 (EMD Millipore,
NE1013, dilution 1:100) plus guinea pig anti-rat TRPV1 (dilution 1:100). All slides were
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allowed to incubate overnight at 4°C. Slides were then treated with goat anti-rabbit Alexa
Fluor 647 (dilution 1:1000), goat anti-mouse Alexa Fluor 647 (dilution 1:1000), or goat antiguinea pig Alexa Fluor 647 (dilution 1:1000) at room temperature in the dark (1 hr). The
stained slides were imaged using a ZEISS LSM 800 confocal microscope after mounting
in either ProLong® Gold antifade mountant with DAPI (Thermo Fisher Scientific, P36931)
or Fluoromount-G® (Southern Biotechnology, 00-4958-02).

3.2.13 Analgesic efficacy study of P-HMP on AIA rats
Hydromorphone hydrochloride (6 mg/kg, n = 10) or P-HMP (HMP equiv. 6 mg/kg,
n = 10) were administered to AIA rats by tail vein injection (i.v., 1 mL/kg). Saline was
injected intravenously as a control (n = 10). The weight distribution between the animal’s
hind limbs was measured using the incapacitance tester. This apparatus consists of two
force transducers capable of measuring the body weight that the animal places on each
hind limb. Animals were placed on the incapacitance tester with their hind paws centered
on the two force transducers, and the average body weight distribution in grams was
calculated over a period of three seconds. The weight bearing score is expressed as a
ratio of the weight placed through the limb ipsilateral to the inflammation versus the sum
of the weights placed through both the contralateral and ipsilateral limbs, with a ratio of
50% resulting from equal weight distribution across both hind limbs. Weight distribution
was measured before induction, before dosing, and at several time intervals following drug
administration, up to seven days.

The tail flick test was performed as a supplemental method to determine whether the
analgesic properties of our prodrug are restricted from off-target effects within the spinal
cord. For this test, rats’ tails were exposed to a focused beam of radiant heat at a point 3
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cm from the tip using the tail flick unit. Tail flick latencies were defined as the interval
between the onset of the thermal stimulus and the reflexive response of the tail. Animals
not responding within 15 sec were removed from the tail flick unit and assigned a
withdrawal latency of 15 sec. Tail flick latencies were measured at pre-induction, predosing, and at several other time points following drug administration, up to seven days.

3.2.15 Statistics
Data are shown as mean ± SD. Statistical analysis was performed using Prism
version 7.03 (GraphPad Software, Inc.). The results of the incapacitance and talk flick
assays where analyzed using two-way ANOVA, and individual groups were compared
using Tukey’s HSD test for multiple comparisons.

3.3 Results
3.3.1 Synthesis and characterization parameters of HPMA-co-HMP conjugates
The synthesis of all three HMP-containing HPMA copolymer conjugates has been
well-established and was undergone with minimal difficulty.

Since the RAFT

polymerization method was employed, the PDIs of the conjugates were relatively narrow
and consistent with one another, as evident in Table 3.1. The drug and fluorescent tag
contents of the copolymers also exhibit homogeneity.
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3.3.2 In vitro release of HMP from P-HMP conjugate
Three different buffer conditions were used to mimic the environments to which the
HMP copolymer conjugate is exposed in vivo (Figure 3.1). The buffer at pH 7.4 reflects
the initial condition of the intravenously-injected prodrug into the bloodstream. Slow
release at this pH is observed over the time course measured. Once the P-HMP is
extravasated to the site of inflammation, a pH of 6.5 often dominates due to increased
glycolysis under the hypoxic conditions present in chronic inflammatory ailments. In
simulating conditions, the drug demonstrates a similar release pattern to that in the neutral
condition, with slightly more rapid, linear release kinetics. Furthermore, uptake of the
prodrug into phagocytic vesicles exposes them to a pH of approximately 5, and it is
apparent that this can result in rapid HMP release from the polymer backbone; ~90% of
the drug content is released within 8 hours in corresponding in vitro conditions.
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Figure 3.1 In vitro release kinetics of P-HMP prodrug. Data are shown as mean ±
standard deviation. All analyses are performed in triplicate.
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3.3.3 Phagocytosis of P-HMP by murine macrophages
The LPS-activated macrophage cells are able to uptake the P-HMP-Alexa
copolymer after 24 hr incubation (Figure 3.2). The drug signal also coincides with the red
fluorescence of the LysoTracker, indicating that the copolymer does indeed reside within
the intracellular degradative organelles.

3.3.4 Near-infrared biodistribution study of P-HMP in AIA rats
There is strong fluorescent signal at the left knee joint at days 1 and 3 post-injection
of the P-HMP-IRDye (Figure 3.3). This sustained near-infrared signal which accumulates
primarily at the site of inflammation is indicative of P-HMP’s ability to preferentially target
areas of leaky vasculature and thereafter be sequestered by local phagocytic infiltrates.

3.3.5 Immunohistochemical analysis of the knee joint
The image panels shown in Figure 3.4 indicate the co-localization of P-HMP
(green) with CD68 (macrophage marker, magenta, panel A) and P4HB (fibroblast marker,
red, panel B) within the ipsilateral knee joints of AIA rats. DAPI (blue) indicates nuclei.
There is visible co-existence of the prodrug with its target µOR (magenta, panel C) and as
well as with the TRPV1 ion channel (red, panel C).
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Figure 3.2 Co-Localization of P-HMP-Alexa prodrug within mouse macrophage
intracellular organelles. Representative confocal microscopy image of RAW 264.7 cells
stained with LysoTracker Red DND 99 (red, lysosome marker) and P-HMP-Alexa
conjugate (green). Nuclei are marked with DAPI (blue). The merged image of all three
fluorescent signals is suggestive of co-localization of the P-HMP with intracellular
lysosomes via the yellow color observed. Scale bars = 20 µm.
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1 day

3 days

Figure 3.3 In vivo visualization of prodrug targeting to arthritic joint. Representative 1day and 3-day post-injection fluorescent images. Signal intensity parameters were
adjusted to the same values for each image.
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Figure 3.4 Representative confocal fluorescence microscopy images of inflammatory
cells (panels A and B) and of the pain-transmitting ion channel TRPV1 and µORs
(panel C) with P-HMP copolymer (green) within the synovium of the arthritic knee joints
1 day post-dosing. Panel A, from left to right: CD68; P-HMP; DAPI; merged. Panel C,
from left to right: TRPV`; µOR; P-HMP; merged. All scale bars = 20 µm.
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3.3.6 Analgesic efficacy of P-HMP on AIA rats
The mean weight distribution ratio (percent weight bearing score, %WBS) were
calculated for each group using the following formula:

𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑛 𝑖𝑛𝑗𝑢𝑟𝑒𝑑 𝑙𝑒𝑔
%𝑊𝐵𝑆 = &
6 ∗ 100
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑛 𝑢𝑛𝑖𝑛𝑗𝑢𝑟𝑒𝑑 𝑙𝑒𝑔 + 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑛 𝑖𝑛𝑗𝑢𝑟𝑒𝑑 𝑙𝑒𝑔

While there is a marked difference in WBS values for the P-HMP versus saline within the
first 8 hours after dosing, there is no significant variation amongst the P-HMP and free
HMP groups at the time points measured. This indicates that the P-HMP exhibits rapid
therapeutic onset and duration similar to the free HMP injection, but the effect does not
last beyond the first day. Statistical significance is observed within the first 8 hours, and
in particular at the onset of dosing, between the saline control and HMP groups, indicative
of the free drug’s immediate analgesic effect. However, there is a delay in analgesic
response observed within the P-HMP group (Figure 3.5).
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Figure 3.5 Percent weight bearing scores (%WBS, or incapacitance) of AIA rats. For
the free HMP group, incapacitance could not be measured from 0-3 hrs post-dosing,
during which time the rats were comatose. **, P < 0.01 P-HMP vs. saline; ***, P < 0.001
P-HMP vs. saline; ****, P < 0.001 P-HMP vs. saline; ##, P < 0.01 HMP vs. saline; ###, P
< 0.001 HMP vs. saline; ####, P < 0.0001 HMP vs. saline.
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For the tail flick test (Figure 3.6), data were expressed as tail flick latency (sec),
and the percentage of the maximal possible effect (%MPE, 15 sec) was calculated as
follows:

%𝑀𝑃𝐸 = &

𝑝𝑜𝑠𝑡𝑑𝑟𝑢𝑔 𝑙𝑎𝑡𝑒𝑛𝑐𝑦 − 𝑝𝑟𝑒𝑑𝑟𝑢𝑔 𝑙𝑎𝑡𝑒𝑛𝑐𝑦
6 ∗ 100
15 𝑠𝑒𝑐 − 𝑝𝑟𝑒𝑑𝑟𝑢𝑔 𝑙𝑎𝑡𝑒𝑛𝑐𝑦

For the HMP (6 mg/kg) group, since rats lost consciousness from 0-3 hrs after drug
administration, tail flick latency was kept at the maximal value. There are significant
differences between the prodrug and the free HMP in their CNS depression effects. While
the free drug is responsible for comatose behavior and significantly increased tail flick
latencies within the first day, the prodrug does not induce unconsciousness and its latency
values return to those of the saline control within the first five hours of administration.
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Figure 3.6 Tail flick latency values of AIA rats. For the free HMP group, tail flick latency
was kept at the maximal value (15 sec) during the time rats were comatose. ††, P < 0.01
P-HMP vs. HMP; †††, P < 0.001 P-HMP vs. HMP; ††††, P < 0.0001 P-HMP vs. HMP; **,
P < 0.01 vs. saline; ***, P < 0.001 vs. saline; ****, P < 0.0001 vs. saline.
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3.4 Discussion
Oftentimes a primary symptom of its underlying disease, the pain associated with
a chronic ailment usually requires potent analgesic therapy with immediate effect. Opioids
such as hydromorphone and fentanyl have shown similar or superior pain modulating
efficacy to over-the-counter NSAID analgesics and acetaminophen,177 highly depending
on the nature of the pain178 and drug tolerability in individual sufferers. In the particular
case of inflammatory conditions like rheumatoid arthritis, long-term opioid therapy is a
mainstay treatment.179

However, with the opioid epidemic reportedly on the rise, a

modified drug approach to improve the pharmacokinetic and biodistribution profiles of
these medications is warranted. It has long since been established the ability of HPMA
polymerics to extravasate into solid tumor tissue via the enhanced permeability and
retention (EPR) effect, due to the polymer’s uncharged and flexible nature which allows
passage through endothelial tissue layers.180 Analogous to tumor targeting, our previous
research104,106,107,138 has proven the ability of HPMA copolymers to passively and
selectively target inflamed tissue through what we have coined as the ELVIS mechanism;
i.e.

Extravasation

through

Leaky

Vasculature

and

Inflammatory

cell-mediated

Sequestration. Furthermore, active transport to the inflammatory lesions of a portion of the
nanomedicine administered may be mediated through sequestration by white blood cells
(WBCs) in the circulation. By administering a synthetic conjugate of the model opioid
hydromorphone (HMP) and a biocompatible HPMA copolymeric carrier, we hypothesized
that the increased vascular permeability present at the arthritic joints would allow
preferential targeting to areas of inflammatory lesion, potentially decreasing the CNS
access of opioids that lead to tolerance, dependence, and addiction.
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According to the results of the weight bearing scores after a single i.v.
administration, the analgesic effect of the polymeric hydromorphone (P-HMP) is almost
identical to that of the free HMP. The slightly delayed therapeutic effect seen with P-HMP
can be construed as a result of the time it takes the macromolecules to permeate into and
extravasate from the network of vessels present at the inflammatory site and to be
activated. As evidenced in the tail flick assay, the spinal cord analgesic effects of P-HMP
vs. HMP is significantly reduced within the first 8 hrs of administration, and almost entirely
eliminated after 5 hrs post-dosing. Spinal cord analgesia is a complex phenomenon,
partially a result of descending mechanisms which modulate the activity of dorsal horn
neurons.

Opioids are known to reduce pain transmission at this level by inhibiting

neurotransmitter release from the dorsal horn. In both the incapacitance and tail flick tests,
the free HMP is demonstrated to have significant analgesic effects. Since the opioid alone
does not have particular affinity for inflammatory pathologies, it is distributed to the area
of arthritis as well as to the spinal cord region upon systemic administration, through
penetration of the BBB. However, data from the tail flick assay indicates that P-HMP does
not cross the BBB or the dorsal horn to give rise to spinal cord analgesia. Because the
tail does not possess inflammatory properties, the macromolecular P-HMP does not
accumulate within this region, and we posit that the existence of modest analgesia within
the P-HMP group at earlier time points is most likely due to the diffusion of hydrolyzed
HMP from the inflammatory depots back into circulation. The arthritic joint-targeting
property of the prodrug is supported in the near infrared imaging-based biodistribution
data as well. Therefore, the two methods here used to measure analgesia together
conclude that our prodrug works strictly peripherally within the inflamed joint. Previous
work has indicated that opioid tolerance is associated with the development of a
compensatory response among spinal cord dorsal horn neurons, contributing to central
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sensitization that ultimately leads to tolerance, dependence, and addiction.181 Given the
results from these experiments, our macromolecular prodrug strategy may thus be able
to allay the detrimental CNS effects commonly associated with opioid use.

The in vitro cell culture and IHC data prove that the prodrug can indeed be
internalized by resident and infiltrating phagocytic immune cells, as shown via the co-local
fluorescence of the Alexa-labeled prodrug with the activated macrophage cell line in vitro
and with the antibody markers for macrophage (CD68) and fibroblast (P4HB) cells in the
ex vivo processed tissues. Moreover, hydromorphone is known to elicit its analgesic
effects through selective binding to opioid receptors, and in particular the mu subtype
(µOR).174 Primary afferent nerves in vertebrate animals exist as pseudounipolar neurons,
wherein their cell body, or soma, resides in the dorsal root ganglion or in the trigeminal
ganglion for cranial nerves.

Mu opioid receptors are expressed on the two axons

emanating from these neural cells, the central projection terminating in the dorsal horn of
the spinal cord and the peripheral projection terminating in the skin or in the organs of the
body. Though it is widely acknowledged that under normal conditions analgesia via mu
opioid receptor agonism is most prominent in the spinal cord and other central nervous
system regions,182 in inflammatory conditions, there is ample evidence of increased
functionality of opioid receptors on primary afferent neurons and even on immune cells.83
Data from the IHC analyses supports this mechanism of pain attenuation that may be
brought about by our peripherally-restricted macromolecular prodrug. In panel C, the
positive fluorescent IHC staining of the µOR receptor co-existent with P-HMP in processed
tissue confirms the presence of the target receptor within the joint synovial cavity and
corroborates our prodrug’s ability to interact with these receptors. In this same slide, the
dual staining of the TRPV1 nociceptive ion channel identifies an important element in the
transmission and modulation of pain. There is substantial co-localization of this channel
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with µOR, as well as with P-HMP. Activation of peripheral opioid receptors on nerve
endings is known to suppress TRPV1 currents via the Gi/o and the cAMP/protein kinase
A pathway.183 In addition, though originally believed to be to be exclusively associated
with sensory neurons, this ion channel has also been identified on immune cells, from
which its manipulation can mediate immune functions such as inflammation.184 In
particular, its suppression in macrophages has been shown to reduce the cellular
production of reactive oxygen species, which play a crucial role in the perpetuation of pain
and inflammation.185 Therefore, through binding to its receptor on immune cells and
possibly on peripheral nerve endings could the hydromorphone mitigate the activities of
co-localized TRPV1 receptors to produce analgesia within the inflamed joint. However,
as the therapeutic data suggests, the 1-day post-dosing analgesic efficacy of P-HMP is
minimal, since HMP may have been entirely cleaved from the prodrug and metabolized
by this time. To further improve the efficacy of the macromolecular HMP prodrug, new
linker chemistry for P-HMP may be designed wherein the hydrolysis rate is adjusted for
sustained release.

This is possible because the fine-tuning of the microchemical

environment of the cleavable linkers, such as hydrazone, in HPMA copolymers are known
to affect the pH-dependent cleavage rate.150 The in vivo imaging data indicates that the
polymer is present at the inflamed tissue site at least three days post-dosing. Therefore,
if a new prodrug design can be employed to afford a P-HMP wherein the activation of HMP
is sustained for a prolonged period of time in vivo, a persistent analgesic effect beyond
the dosing day may be achieved. Optimization of the HPMA copolymer molecular weight
could also prove to be a valuable strategy to improve the pharmacokinetic and
biodistribution profile of the P-HMP prodrug, extending its retention within the inflammatory
regions and therefore requiring less frequent dosing than with the free drug alone, which
can reduce toxic metabolite accumulation and adverse effects on the CNS.

Future

therapeutic efficacy studies should also include repeated dosing regimens, the data from
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which could further demonstrate the superior efficacy and safety of the macromolecular
prodrug design as a new class of analgesic.

3.5 Conclusion
A macromolecular prodrug of hydromorphone, a potent analgesic, has been
successfully synthesized and characterized. We administered it as a single i.v. injection
in a rodent model of monoarticular adjuvant-induced arthritis (AIA). In addition to an
analgesic effect similar to the dose equivalent HMP, the prodrug demonstrated
significantly attenuated spinal cord analgesia. This may be attributed to the prodrug’s
ability to preferentially target the site of inflammation, where it is internalized, activated via
the phagocytic cells and readily accessible to local peripheral nerves. Through this local
targeting mechanism, the prodrug may mitigate opioid-induced tolerance, dependence,
and addition. With further structural optimization, we anticipate to create a P-HMP with
potent and sustained analgesic effect and no off-target analgesia. In the future, these
development schemes could be extrapolated to other analgesics for the more effective
and safe management of chronic inflammatory pain.
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CHAPTER 4
SUMMARY

Chronic pain can exist in many forms, and is undoubtedly a major element in
countless diseases afflicting millions worldwide. Rheumatoid arthritis (RA), in particular,
is a chronic autoimmune inflammatory health condition distinguished by joint pain and
swelling. If unhampered by the lack of proper use of pharmaceutical therapy, RA can
not only cause permanent joint damage, but the distressing pain along with other comorbidities can significantly lower a patient’s quality of life. Control of this pain alone is
pivotal to the well-being of RA sufferers. Current pain management strategies include
the use of several different types of analgesics, all of which relieve discomfort through
varying mechanisms. However, each class of these drugs introduces its own systemic
side effects.

There remains a need for more targeted, efficient delivery of these

medications for sustained therapeutic benefit with minimal off-target risks.

Previous work in our laboratory has demonstrated the ability of macromolecular
prodrug strategies to preferentially accumulate within inflammatory arthritic regions in
rodent models simulating the conditions of RA. Dexamethasone (Dex), a commonlyprescribed antirheumatic GC, has been used in clinical practice for decades to decrease
inflammation associated with RA. It has been established that systemic administration
of an HPMA copolymer-Dex conjugate can effectively be relayed to inflamed lesions
through extravasation of leaky vasculature and subsequent cell-mediated sequestration,
a passive-targeting phenomenon known as the ELVIS mechanism. Its superior efficacy
versus free Dex alone has been verified. With regards to my thesis work, the analgesic
capabilities of this a prodrug conjugate was an avenue that had not yet been explored.
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Through augmentation of many of the established protocols that have been used prior
in various studies with P-Dex, insights into the pain relief mechanisms of the prodrug
were studied. Moreover, using the same polymeric platform and synthetic strategies,
another widely used opioid analgesic, hydromorphone (HMP), was utilized to test its
efficacy in relieving the pain coexistent with inflammatory arthritis.

In Chapter 2, I have presented my studies on the pain-alleviating effects of a pHsensitive macromolecular prodrug of Dex. This P-Dex prodrug had been previously
validated in our laboratory as a superior antirheumatic in several inflammatory models.
As seen before with its synthesis, the P-Dex used in these experiments was verifiably
well-defined with narrow polydispersity and appreciable drug loading. Dexamethasone
was successfully conjugated to the HPMA copolymer backbone via an acid-cleavable
hydrazone linker, allowing for drug activation within the acidic milieu of inflamed synovial
tissues. In vivo imaging studies confirmed the presence of the P-Dex copolymer within
the synovium up to three weeks after a single i.v. injection, and on a more detailed level,
immunohistofluorescent analyses further illustrated the specific immune cell uptake of
the prodrug. The superior inflammation-treating properties of our P-Dex macromolecular
prodrug were validated in the histological scorings of the synovium. Micro-CT imaging
illustrated the exceptional bone protective effects of P-Dex as well. Most pertinent to
the purpose of my thesis work, sustained analgesia was indirectly confirmed through the
incapacitance studies with P-Dex rats, suggesting efficient drug activation at the target
inflammatory site. Moreover, quelling of the peripheral edema due to enhanced vascular
permeabililty in the inflamed hindlimbs was seen with the limb diameter measurements,
as is expected from our prior studies in AIA models with P-Dex.
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Chapter 3 utilized much of the same approaches and methodologies used with
P-Dex to determine the therapeutic efficacy of an HPMA-based prodrug of the common
opioid hydromorphone (HMP). A similar route as with the P-Dex was applied to the
synthesis of P-HMP.

Again, the copolymer was successfully synthesized and

characterized to be of narrow polydispersity and to have sufficient drug loading, and the
in vitro release profile demonstrated the pH-dependent cleavage of HMP. Cell culture
investigations using a murine macrophage cell line suggested that the copolymer is
phagocytosed by activated macrophages and subsequently trafficked within subcellular
endosomes.

Following this, the in vivo near-infrared imaging studies of P-HMP

illustrated its passive targeting and retention within the inflamed knee joints of AIA rats.
Immunohistofluorescent analyses of the arthritic joints further confirmed that the
retentive qualities of P-HMP is indeed attributed to its internalization by immune cells,
namely, fibroblast-like synoviocytes (FLS) and macrophages, within the synovium and
synovial cavity. The co-existence of the immune cell-internalized prodrug with peripheral
nerve endings expressing TRPV1, an ion channel ligand important in pain modulation
and transmission, suggests a mechanism by which P-HMP alleviates pain in arthritic
joints. Comparable analgesia was attained with P-HMP versus an equivalent dose of
the free drug, though this was not sustained beyond the day of drug administration.
Spinal cord analgesia observed upon free opioid intake, however, was greatly reduced
in those animals receiving the prodrug, as evinced by the tail flick assay. This indicates
our prodrug’s ability to hinder BBB passage of these drugs. Structural optimization of
the P-HMP prodrug could increase the duration of its analgesic potential, as well as
further minimize CNS impact.

99

Future Studies
1) The analgesic effects the two prodrugs studied herein can be maximized
through tailoring the properties of the copolymers to further sustain and enhance their
therapeutic activities. Previous work within our laboratory has demonstrated the PK/BD
effects of modifying the P-Dex copolymer weight average molecular weight (Mw) and
drug content. It was discovered154 that the prodrug with the highest Mw, albeit at a
threshold of ~45,000 Da to facilitate renal clearance, and with the highest Dex content
of ~300 µmol/g copolymer displayed the most arthrotropism in a rat model of AIA within
the ankle joint. This is due to the increased circulation half-life of the conjugates and
presumably enhanced inﬂammatory cell uptake at the sites of inﬂammation.

These

findings were supported in a mouse model mimicking orthopedic prosthetic failure via
aseptic implant loosening.104 Similar studies should be performed to determine if these
modulations affect the pain-relieving characteristics of P-Dex. Furthermore, to improve
the pain-ameliorating efficacy of the P-HMP prodrug to beyond the dosing day, a design
strategy could be employed to more gradually cleave the HMP from the polymer
backbone within the inflamed synovium. As alluded to before, the chemical composition
and functional groups near the prodrug cleavage sites affect the rates of scission at any
given pH. A strategy to be tested includes introduction of electron delocalization via
phenyl rings on the polymer backbone. Moreover, conversion of the hydromorphone
carbonyl six-membered ring into its corresponding ketal would substitute the hydrazone
bond for a more chemically stable acid-catalyzed cleavage site. Optimization of the
HPMA copolymer molecular weight and drug content, such as has been done with PDex, could also prove to be a valuable strategy to improve the PK/BD profile of the PHMP prodrug, extending its retention within the inflammatory regions and therefore
requiring less frequent dosings than with the free drug alone, which can reduce toxic
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metabolite accumulation. Repetition of the therapeutic efficacy studies should include
repeated dosing regimens, data from which could further demonstrate the superior
qualities of our prodrug method of analgesic conjugation.

2)

While

the

safety

profiles

of

HPMA

copolymer

conjugates

as

chemotherapeutics are regarded as acceptable,186,187 there remains such validations to
be carried out in models resembling RA using HPMA copolymers with analgesic moieties
as the active pharmaceutical substances. One major hurdle in these studies is that of
the murine models used to mimic human RA, barring the use of non-human primates
which would better imitate the clinical scenario, but for reasons such as cost are often
not a feasible option in upstream preclinical research. The cytokine pathways and
immunologic mechanisms differ in each rodent model used for these studies.
Particularly, the commonly-used AIA and collagen-induced arthritis (CIA) variants
engender the disease for durations not long enough to properly conduct long-term safety
and toxicity testing. Rats with AIA generally experience disease resolution after about
a month,188 and the late stages of CIA (around 6 to 8 weeks) display highly declined RA
pathological characteristics, such as a significant decrease of inflammatory infiltrates
within the inflamed synovial tissues.189 Rodent models with a prolonged disease course
are, however, achievable. This can be done with spontaneously-developing arthritis
prototypes such as the K/BxN mouse.190 These mice express both the T cell receptor
(TCR) transgene KRN and the MHC class II molecule Ag7. Autoimmunity is initiated by
TCR recognition of a peptide derived from glucose 6 phosphate isomerase, which is
presented to the immune system by the aforementioned MHC molecule.

Typically,

clinically visible signs of inflammation are observed at 3 weeks of age and progress to
chronic, inflammatory-erosive arthritis within 4 to 8 weeks of age. Histological studies
have shown many parallels between this disease model and the human manifestation of
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RA, such as pannus formation and elevated inflammatory cytokines within the synovial
fluids of multiple joints.191 Another mouse strain that may be able to recapitulate the
lifelong disease course of RA is the TNF-transgenic model expressing a human TNF gene
lacking post-transcriptional regulatory elements.192

Here, the disease progresses to

maximal severity between 12 and 16 weeks of onset, and animal lifespans can last over
a year. These features, along with the similarities to human RA, compels the use of this
model in long-term toxicity investigations with HPMA copolymer conjugates.

3) Other murine models of chronic inflammatory pain can be used to more
comprehensively assess the effect of our analgesic prodrugs in various conditions.
Nanomedicine formulations like those based on HPMA copolymers can capitalize on the
pathological traits of inflammatory afflictions to improve drug distribution and retention at
the target sites. These features, such as angiogenesis, leaky vasculature, and a high
density of phagocytic immune cells within the inflamed regions, are present in disease
models other than those simulating RA. One major disease that has here been touched
upon is that of cancer of various types.

Many macromolecular chemotherapeutic

strategies have been researched and implemented with great success. Though the
mechanism of macromolecular retention differs from that of other inflammatory
pathologies, pain can ensue as a result of cancer etiologies and it may be useful to test
our analgesic prodrugs in models of tumor-related pain evoked by local xenografts of
cancer cells. Additionally, osteoarthritis (OA), a painful degenerative disease caused by
cartilage erosion, is the most common chronic condition of the joints.193 It lacks the
synovial presence of neutrophils as well as other systemic manifestations of inflammation
and has therefore historically been considered to be a non-inflammatory arthropathy.
However, patients display common hallmarks of inflammation such as pain, edema, and
low mobility.

The discovery of inflammatory mediators produced by activated
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chondrocytes and synoviocytes, as well as recognition of the increased vascularization
component partially due to depletion of articular cartilage’s endogenous angiogenesis
inhibitors, have led to the awareness that OA does indeed have an appreciable
inflammatory element.194 The effectiveness of passively-targeting NPs for diagnosis and
treatment has been validated in murine models of OA, so it stands to reason that our
particular prodrugs can have significant impact on the pain related to this pathology. Other
pain models on which the prodrugs can be evaluated include that of inflammatory bowel
disease (IBD), of which the visceral pain associated can be induced by chemostimulation
of the colon using capsaicin.195 Alternatively, a way to establish the disease itself is
through disruption of the intestinal epithelial barrier using dextran sulfate sodium (DSS),
causing entry of luminal bacteria into the surrounding mucosa and generating an
inflammatory response that reflects the symptoms in patients with ulcerative colitis.196

4) Along with varying the disease type, it would be useful to engage other methods
of pain and of CNS depression and addiction measurement to more completely
understand the nociceptive, neuropathic, and neurological effects of a particular pain
model and the results of its therapeutic intervention. While in clinical scenarios the
assessment of pain is based on self-reported scores from individual patients, the
determination of its severity in animal models for research must rely on other telltale signs
or behaviors, usually upon application of an external stimulus. For example, the von Frey
hair mechanosensitivity test is used to determine the peripheral and mechanical
sensitization caused by the inflammatory response. von Frey hairs, which are a graded
series of thin, calibrated ﬁlaments that bend to exert a speciﬁc mechanical force, are
applied to the plantar surface of the paws of restrained animals. Inflamed tissues are
withdrawn at a reduced threshold versus non-inflamed paws, owing to the hypersensitivity
that is induced by both peripheral and central mechanisms in the disease pathology.
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However, the stress caused by forceful restraint of the animal can complicate the
interpretation of the results.

One option to eradicate this variable is known as the

Hargreaves test, which measures thermal hyperalgesia of unrestrained animals. Here,
radiant heat from a moving heat source is gradually increased underneath the plantar
surface of the hindpaw until the animal withdraws.197 An even less physically encroaching
option assesses spontaneous animal behaviors through measuring their locomotor activity
in a novel environment. Developed by Mason, et al, this method is known as the reduction
in spontaneous activity by adjuvant (RSAA) test.198 Animals are placed in a Plexiglass
box equipped with sensors that detect changes in motion. Distance travelled and vertical
activity (rearing) can be measured before and after administration of an inflammatory
agent, and at different time points throughout the drug treatment period to determine
locomotor deficits and whether these can be reversed by administered therapeutics.
Moreover, the Laboratory Animal Behavior Observation, Registration and Analysis
System (LABORAS) is an automated system that can be utilized to detect miniscule
changes in the vibration signatures associated with various behaviors such as eating,
drinking, grooming, and locomotion.199 These last two methods largely do away with
observational bias of individual experimenters.

Electrophysiological approaches can

further offer insight into the activities of particular nociceptor nerve endings. Peripheral
sensitization of primary afferent nerves is an aftereffect of increased voltage-gated
Ca2+ currents. It has been theorized that these nerves also redistribute to central or
peripheral terminals, contributing to inflammation-induced increases in afferent input.200
Through understanding the mechanisms of our analgesic prodrugs that lead to the
resolution of nerve overactivity, we could gain a more thorough perspective of the
prodrugs’ pain-alleviating capabilities and perhaps use this knowledge to more tightly
control their somatosensory effects. In addition, direct measures of CNS depression and
addiction for narcotics such as opioids can be tested to quantitatively measure the
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neuropharmacological effects.201 The rota-rod performance assay can evaluate balance,
grip strength, and motor coordination of subjects to determine whether a drug induces
motor impairment and which components of neurons carry out the effects of specific
agonists or antagonists.

Similarly, the actophotometer performance test monitors

locomotor behavior, with decreased activity pointing towards CNS depression. Animal
models of repeated drug administration can also be implemented to perhaps provide
predictive validity concerning whether our prodrug approach could significantly reduce the
addictive potential of opioids.202 Drug reinstatement experiments train animals to selfadminister a drug, upon which the animals are subjected to conditions of nonreinforcement
until operant responding is largely eradicated. Here, stimuli could be presented with the
goal of reinstating drug-seeking behavior, such as lever pressing, measured under drugfree conditions, and an increase in the number of operant responses compared with that
observed during extinction is interpreted as an increase in drug-seeking behavior. The
conditioned place preference (CPP) paradigm involves daily drug injections paired with a
compartment in a conditioning box, while a second compartment is paired with vehicle
control injections. Drug-conditioned place preference could be achieved after several
days of administration, and the preference is extinguished upon repeated vehicle
injections. Reinstatement of CPP is carried out through drug priming, allowing screening
of drug-seeking behavior of the free drug itself versus the same injection regimens of the
prodrug. These procedures, among others, could afford valuable insight into whether the
prodrug approach protects against depressive symptoms and addictive behaviors which
reflect CNS interaction of narcotic analgesics.

5) Rather than use model drugs with ubiquitous targets like the GCRs or the
µORs, higher precision might be attained by conjugation of a more specifically-targeted
ligand to the HPMA copolymer backbone. This brings into the foreground the JAK 3
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inhibitor Tofa, which, as mentioned in the introductory chapter, has been extensively
researched and is approved for use in treating RA as well as ulcerative colitis. Our
laboratory has determined the superior anti-inflammatory effects of an HPMA-based
Tofa copolymer versus free drug alone in the AIA rat model.203 It has yet to be tested
for its direct effects on the pain associated with arthritic conditions.

Less potent

pharmaceuticals such as NSAIDs may also be greatly augmented through the prodrug
strategy and yield improved PK/BD and toxicity profiles. When taken in combination
with other prodrugs such as our P-Dex, the resulting decreased dosages of each
copolymer would likely even further improve the side effects associated with each drug
while effectively maintaining adequate analgesia and overall therapeutic benefit.
Alternatively, changing the excipient used for pharmaceutical conjugation may be
considered. Since HPMA is not biodegradable, its intact copolymers must be excreted
through the kidneys to avoid long-term adverse effects, and therefore they must adhere
to certain size limitations. However, the size requirements and renal excretion of these
prodrugs prevents their longer circulation and higher accumulation at the target sites.
Market approval might be more quickly observed with biodegradable polymer substitutes
that exhibit sufficient in vivo stability to allow for adequate biodistribution. There have
been numerous strategies for this using a variety of biologically degradable substances,
among which include polymers of α-amino acids such as L-lysine, L-glutamic acid, and
(N-hydroxyalkyl)glutamine, as well as carbohydrate polymers such as dextrins,
hydroxyethylstarch (HES), and polysialic acid, all of which do not produce toxic byproducts.204 Moreover, there have been studies involving the synthesis and therapeutic
evaluation of biodegradable derivatives of traditional polymers like PEG and HPMA
copolymers. Many of these high-molecular-weight drug conjugates have been tested
for anticancer efficacy in a number of tumor models.205,206 Typical copolymer strategies
include grafting of lower-molecular-weight polymers attached to a primary polymer
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backbone via linkers susceptible to enzymatic or reductive degradation, such as
oligopeptides or disulfide bonds, respectively.207,208 This can yield a structure with high
molecular weight and fairly narrow weight distribution.

The smaller grafts are

subsequently cleaved in vivo, fragmenting the copolymer into segments excretable
through glomerular filtration in the kidneys.

6) While we have confirmed that both P-Dex and P-HMP are indeed internalized
by resident macrophages within the inflamed joint synovium, a clearer outlook of the
immune processes these copolymers may affect could be accomplished by identification
of the specific macrophage lineage(s) that uptake(s) the macromolecular structures.
Defined as M1 and M2 macrophages, the former induces prototypic inflammatory
responses through Th1 interaction and IFN-γ and LPS stimulation, leading to their
production of toxic nitric oxide and reactive oxygen intermediates, while the latter is
stimulated in the alternative pathway through, for instance, IL-4 produced by Th2 cells.209
M1 macrophages are irreplaceable during acute infectious diseases and provide host
protection against intracellular bacteria or viruses, yet their prolonged existence is harmful
and thus tissue repair and restoration is necessary. This is where the M2 macrophages
come into play, since they are responsible for that tissue repair, although they also help
to perpetuate chronic infectious diseases. Altogether, the M1 phenotype is deemed proinflammatory, while the M2 macrophage lineage is anti-inflammatory.

The different

macrophage types vary in their receptor expression, rendering it hypothetically possible
to immunohistochemically identify whether M1 or M2 macrophages primarily phagocytose
the prodrugs. The in vitro cell culture experiment with P-HMP included the use of LPS for
stimulation, and it was confirmed that these classically-activated macrophages can
internalize our prodrugs.

Additionally, previous experiments within our lab have

corroborated the same internalization mechanism of P-Dex.210 However, the situation is
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obviously much more complicated in vivo. In a study identifying typical M1/M2-associated
cytokines expression, it has been found that systemic delivery of a glucocorticoid
liposomal formulation in a mouse AIA model inhibits M1 macrophages in favor of the M2
phenotype within the synovial lining, and may drive their strong suppressive effect.211
Though it has classically been difficult to immunohistochemically identify macrophage
types in vivo, since a dynamic spectrum of phenotypes exist in these conditions, studies
have deciphered genes that exist commonly or exclusively to one macrophage type.212
The marker used in this thesis work, that for CD68, detects macrophages of all subsets in
tissue sections. However, this marker may also identify dendritic cell subsets.213 The
phosphorylated form of signal transducer and activator of transcription 1 (pSTAT1) binds
to the promoter region of interferon-stimulated genes, and can be used in combination
with CD68 or CD163 generic macrophage markers to identify M1 polarized macrophages.
Moreover, either CD68 or CD163 together with CMAF, an essential transcription factor for
anti-inflammatory IL-10 expression in macrophages, can detect the M2 lineage. Through
IHC identification of the macrophage phenotypes that uptake our prodrugs in vivo, we
could determine whether our P-Dex indeed favors anti-inflammatory macrophage
differentiation and uptake, and whether our P-HMP prodrug follows suit to at least partially
elicit its analgesic effects through abatement of inflammatory conditions. In addition, the
macrophage phenotypes vary with different stages of disease. Therefore, it may be useful
to detect which macrophages internalize our prodrugs at various time points after disease
initiation, to help uncover mechanisms involved in bringing about their analgesic effects.
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